
The following have been reloaded with a version change:
  1) GCCcore/9.3.0 => GCCcore/8.3.0
  2) binutils/2.34-GCCcore-9.3.0 => binutils/2.32-GCCcore-8.3.0
  3) zlib/1.2.11-GCCcore-9.3.0 => zlib/1.2.11-GCCcore-8.3.0


The following have been reloaded with a version change:
  1) GCCcore/8.3.0 => GCCcore/9.3.0
  2) binutils/2.32-GCCcore-8.3.0 => binutils/2.34-GCCcore-9.3.0
  3) zlib/1.2.11-GCCcore-8.3.0 => zlib/1.2.11-GCCcore-9.3.0

2021-01-23 10:26:12 | INFO | fairseq_cli.generate | Namespace(all_gather_list_size=16384, beam=5, bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', cpu=False, criterion='cross_entropy', data='../../../data-bin/custom_EMEA/short_EMEA', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eval_bleu=True, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, left_pad_source='True', left_pad_target='False', lenpen=1, load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_sentences=128, max_source_positions=1024, max_target_positions=1024, max_tokens=None, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, momentum=0.99, nbest=1, no_beamable_mm=False, no_early_stop=False, no_progress_bar=False, no_repeat_ngram_size=0, no_seed_provided=True, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer='nag', path='../checkpoints/EMEA_11/checkpoint_best.pt', prefix_size=0, print_alignment=False, print_step=False, profile=False, quantization_config_path=None, quiet=False, remove_bpe='@@ ', replace_unk=None, required_batch_size_multiple=8, results_path=None, retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, score_reference=False, scoring='sacrebleu', seed=1, shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, target_lang=None, task='translation', temperature=1.0, tensorboard_logdir='', threshold_loss_scale=None, tokenizer=None, tpu=False, truncate_source=False, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, warmup_updates=0, weight_decay=0.0)
2021-01-23 10:26:13 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-01-23 10:26:13 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-01-23 10:26:13 | INFO | fairseq.data.data_utils | loaded 320 examples from: ../../../data-bin/custom_EMEA/short_EMEA/test.de-en.de
2021-01-23 10:26:13 | INFO | fairseq.data.data_utils | loaded 320 examples from: ../../../data-bin/custom_EMEA/short_EMEA/test.de-en.en
2021-01-23 10:26:13 | INFO | fairseq.tasks.translation | ../../../data-bin/custom_EMEA/short_EMEA test de-en 320 examples
2021-01-23 10:26:13 | INFO | fairseq_cli.generate | loading model(s) from ../checkpoints/EMEA_11/checkpoint_best.pt
S-122	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-122	Place the vials on a flat clean surface .
H-122	-0.6503857374191284	Put the vials on an even surface .
D-122	-0.6503857374191284	Put the vials on an even surface .
P-122	-2.9948 -1.9992 -0.1190 -0.1223 -0.1100 -0.1204 -0.4871 -0.6725 -0.1769 -0.1763 -0.1757
S-195	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-195	- Use within three hours after reconstitution .
H-195	-0.23055045306682587	- Use within three hours after reconstitution .
D-195	-0.23055045306682587	- Use within three hours after reconstitution .
P-195	-0.1523 -0.0944 -0.0702 -0.9269 -0.0802 -0.2900 -0.1626 -0.1772 -0.1664 -0.1853
S-95	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-95	- Use within three hours after reconstitution .
H-95	-0.23055045306682587	- Use within three hours after reconstitution .
D-95	-0.23055045306682587	- Use within three hours after reconstitution .
P-95	-0.1523 -0.0944 -0.0702 -0.9269 -0.0802 -0.2900 -0.1626 -0.1772 -0.1664 -0.1853
S-120	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-120	- Use within three hours after reconstitution .
H-120	-0.23055045306682587	- Use within three hours after reconstitution .
D-120	-0.23055045306682587	- Use within three hours after reconstitution .
P-120	-0.1523 -0.0944 -0.0702 -0.9269 -0.0802 -0.2900 -0.1626 -0.1772 -0.1664 -0.1853
S-170	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-170	- Use within three hours after reconstitution .
H-170	-0.23055045306682587	- Use within three hours after reconstitution .
D-170	-0.23055045306682587	- Use within three hours after reconstitution .
P-170	-0.1523 -0.0944 -0.0702 -0.9269 -0.0802 -0.2900 -0.1626 -0.1772 -0.1664 -0.1853
S-145	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-145	- Use within three hours after reconstitution .
H-145	-0.23055045306682587	- Use within three hours after reconstitution .
D-145	-0.23055045306682587	- Use within three hours after reconstitution .
P-145	-0.1523 -0.0944 -0.0702 -0.9269 -0.0802 -0.2900 -0.1626 -0.1772 -0.1664 -0.1853
S-221	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-221	- Use within three hours after reconstitution .
H-221	-0.23055045306682587	- Use within three hours after reconstitution .
D-221	-0.23055045306682587	- Use within three hours after reconstitution .
P-221	-0.1523 -0.0944 -0.0702 -0.9269 -0.0802 -0.2900 -0.1626 -0.1772 -0.1664 -0.1853
S-72	Welchen Nutzen hat Advate in diesen Studien gezeigt ?
T-72	What benefit has Advate shown during the studies ?
H-72	-0.2692629098892212	What benefit has Advate shown during the studies ?
D-72	-0.2692629098892212	What benefit has Advate shown during the studies ?
P-72	-0.0330 -0.0186 -0.1492 -1.5777 -0.0991 -0.0562 -0.1948 -0.1498 -0.3241 -0.1759 -0.1836
S-97	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-97	Place the vials on a flat clean surface .
H-97	-0.6503857374191284	Put the vials on an even surface .
D-97	-0.6503857374191284	Put the vials on an even surface .
P-97	-2.9948 -1.9992 -0.1190 -0.1223 -0.1100 -0.1204 -0.4871 -0.6725 -0.1769 -0.1763 -0.1757
S-134	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-134	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-134	-0.2824244797229767	Diarrhoea Upper abdominal pain Nausea Vomiting
D-134	-0.2824244797229767	Diarrhoea Upper abdominal pain Nausea Vomiting
P-134	-1.0476 -0.0590 -0.0429 -0.0408 -0.6874 -0.3645 -0.2254 -0.0240 -0.1211 -0.2003 -0.6381 -0.0361 -0.7055 -0.0266 -0.1187 -0.1808
S-147	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-147	Place the vials on a flat clean surface .
H-147	-0.6503857374191284	Put the vials on an even surface .
D-147	-0.6503857374191284	Put the vials on an even surface .
P-147	-2.9948 -1.9992 -0.1190 -0.1223 -0.1100 -0.1204 -0.4871 -0.6725 -0.1769 -0.1763 -0.1757
S-197	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-197	Place the vials on a flat clean surface .
H-197	-0.6503857374191284	Put the vials on an even surface .
D-197	-0.6503857374191284	Put the vials on an even surface .
P-197	-2.9948 -1.9992 -0.1190 -0.1223 -0.1100 -0.1204 -0.4871 -0.6725 -0.1769 -0.1763 -0.1757
S-311	Tablette mit veränderter Wirkstofffreisetzung
T-311	Oral use Oral use Oral use Oral use Oral use Oral use
H-311	-0.9514459371566772	Tablet with altered release of active substance
D-311	-0.9514459371566772	Tablet with altered release of active substance
P-311	-3.1002 -0.2893 -0.4886 -0.0634 -2.4678 -0.1594 -1.0196 -0.5316 -0.4431
S-223	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-223	Place the vials on a flat clean surface .
H-223	-0.6503857374191284	Put the vials on an even surface .
D-223	-0.6503857374191284	Put the vials on an even surface .
P-223	-2.9948 -1.9992 -0.1190 -0.1223 -0.1100 -0.1204 -0.4871 -0.6725 -0.1769 -0.1763 -0.1757
S-2	Reproduction is authorised provided the source is acknowledged .
T-2	Reproduction is authorised provided the source is acknowledged .
H-2	-0.09393279254436493	Reproduction is authorised provided the source is acknowledged .
D-2	-0.09393279254436493	Reproduction is authorised provided the source is acknowledged .
P-2	-0.1040 -0.1557 -0.1196 -0.0115 -0.1051 -0.0120 -0.1197 -0.0582 -0.1111 -0.0136 -0.1388 -0.1780
S-302	Reproduction is authorised provided the source is acknowledged .
T-302	Reproduction is authorised provided the source is acknowledged .
H-302	-0.09393279254436493	Reproduction is authorised provided the source is acknowledged .
D-302	-0.09393279254436493	Reproduction is authorised provided the source is acknowledged .
P-302	-0.1040 -0.1557 -0.1196 -0.0115 -0.1051 -0.0120 -0.1197 -0.0582 -0.1111 -0.0136 -0.1388 -0.1780
S-172	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-172	Place the vials on a flat clean surface .
H-172	-0.6503857374191284	Put the vials on an even surface .
D-172	-0.6503857374191284	Put the vials on an even surface .
P-172	-2.9948 -1.9992 -0.1190 -0.1223 -0.1100 -0.1204 -0.4871 -0.6725 -0.1769 -0.1763 -0.1757
S-310	Tablette mit veränderter Wirkstofffreisetzung
T-310	Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet
H-310	-0.9514459371566772	Tablet with altered release of active substance
D-310	-0.9514459371566772	Tablet with altered release of active substance
P-310	-3.1002 -0.2893 -0.4886 -0.0634 -2.4678 -0.1594 -1.0196 -0.5316 -0.4431
S-109	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-109	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-109	-0.2824244797229767	Diarrhoea Upper abdominal pain Nausea Vomiting
D-109	-0.2824244797229767	Diarrhoea Upper abdominal pain Nausea Vomiting
P-109	-1.0476 -0.0590 -0.0429 -0.0408 -0.6874 -0.3645 -0.2254 -0.0240 -0.1211 -0.2003 -0.6381 -0.0361 -0.7055 -0.0266 -0.1187 -0.1808
S-96	- Nach Rekonstitution nicht mehr kühlen .
T-96	- Do not refrigerate the preparation after reconstitution .
H-96	-0.3244897723197937	- Do not refrigerate after reconstitution .
D-96	-0.3244897723197937	- Do not refrigerate after reconstitution .
P-96	-0.1821 -0.0732 -0.1186 -1.8525 -0.6911 -0.1062 -0.1264 -0.2152 -0.1311 -0.0886 -0.1240 -0.1847
S-146	- Nach Rekonstitution nicht mehr kühlen .
T-146	- Do not refrigerate the preparation after reconstitution .
H-146	-0.3244897723197937	- Do not refrigerate after reconstitution .
D-146	-0.3244897723197937	- Do not refrigerate after reconstitution .
P-146	-0.1821 -0.0732 -0.1186 -1.8525 -0.6911 -0.1062 -0.1264 -0.2152 -0.1311 -0.0886 -0.1240 -0.1847
S-284	Im Zweifelsfall fragen Sie Ihren Arzt .
T-284	If you are unsure about this , ask your doctor .
H-284	-0.24741382896900177	If in any doubt , ask your doctor .
D-284	-0.24741382896900177	If in any doubt , ask your doctor .
P-284	-0.6278 -0.1292 -0.7191 -0.0607 -0.1834 -0.2272 -0.1548 -0.0585 -0.1434 -0.1700
S-121	- Nach Rekonstitution nicht mehr kühlen .
T-121	- Do not refrigerate the preparation after reconstitution .
H-121	-0.3244897723197937	- Do not refrigerate after reconstitution .
D-121	-0.3244897723197937	- Do not refrigerate after reconstitution .
P-121	-0.1821 -0.0732 -0.1186 -1.8525 -0.6911 -0.1062 -0.1264 -0.2152 -0.1311 -0.0886 -0.1240 -0.1847
S-24	Vitamin D einmal pro Tag wurde nicht untersucht .
T-24	The equivalence of intake of 5600 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 800 IU has not been studied .
H-24	-0.24083568155765533	Vitamin D once a day has not been studied .
D-24	-0.24083568155765533	Vitamin D once a day has not been studied .
P-24	-1.0018 -0.0593 -0.0963 -0.2097 -0.3107 -0.2740 -0.1378 -0.1182 -0.1483 -0.2188 -0.1373 -0.1779
S-300	Wofür sollte Advexin angewendet werden ?
T-300	What was Advexin expected to be used for ?
H-300	-0.5341392159461975	What Advexin should be used for 2.
D-300	-0.5341392159461975	What Advexin should be used for 2.
P-300	-0.1775 -4.0377 -0.1460 -0.1534 -0.2230 -0.1255 -0.1324 -0.1262 -0.0502 -0.1695
S-196	- Nach Rekonstitution nicht mehr kühlen .
T-196	- Do not refrigerate the preparation after reconstitution .
H-196	-0.3244897723197937	- Do not refrigerate after reconstitution .
D-196	-0.3244897723197937	- Do not refrigerate after reconstitution .
P-196	-0.1821 -0.0732 -0.1186 -1.8525 -0.6911 -0.1062 -0.1264 -0.2152 -0.1311 -0.0886 -0.1240 -0.1847
S-171	- Nach Rekonstitution nicht mehr kühlen .
T-171	- Do not refrigerate the preparation after reconstitution .
H-171	-0.3244897723197937	- Do not refrigerate after reconstitution .
D-171	-0.3244897723197937	- Do not refrigerate after reconstitution .
P-171	-0.1821 -0.0732 -0.1186 -1.8525 -0.6911 -0.1062 -0.1264 -0.2152 -0.1311 -0.0886 -0.1240 -0.1847
S-222	- Nach Rekonstitution nicht mehr kühlen .
T-222	- Do not refrigerate the preparation after reconstitution .
H-222	-0.3244897723197937	- Do not refrigerate after reconstitution .
D-222	-0.3244897723197937	- Do not refrigerate after reconstitution .
P-222	-0.1821 -0.0732 -0.1186 -1.8525 -0.6911 -0.1062 -0.1264 -0.2152 -0.1311 -0.0886 -0.1240 -0.1847
S-89	Verletzung , Vergiftung und durch Eingriffe
T-89	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-89	-0.31500399112701416	Injury , poisoning and procedural complications
D-89	-0.31500399112701416	Injury , poisoning and procedural complications
P-89	-0.9594 -0.0716 -0.1696 -0.4947 -0.2948 -0.2425 -0.2598 -0.0119 -0.1320 -0.5544 -0.1852 -0.4041
S-100	Nur klare , farblose Lösungen verwenden .
T-100	Only a clear and colourless solution should be used .
H-100	-0.15559077262878418	Use only clear , colourless solutions .
D-100	-0.15559077262878418	Use only clear , colourless solutions .
P-100	-0.1192 -0.3297 -0.1737 -0.1468 -0.1704 -0.0744 -0.1009 -0.1164 -0.1484 -0.1760
S-73	Die Genehmigung wurde am 2. März 2009 verlängert .
T-73	The marketing authorisation was renewed on 2 March 2009.
H-73	-0.3528722822666168	The marketing authorisation was renewed on 2 March 2006.
D-73	-0.3528722822666168	The marketing authorisation was renewed on 2 March 2006.
P-73	-0.0895 -0.0230 -0.0150 -0.0800 -0.1714 -0.1035 -0.0899 -0.1246 -1.0974 -0.2636 -1.9812 -0.1954
S-150	Nur klare , farblose Lösungen verwenden .
T-150	Only a clear and colourless solution should be used .
H-150	-0.15559077262878418	Use only clear , colourless solutions .
D-150	-0.15559077262878418	Use only clear , colourless solutions .
P-150	-0.1192 -0.3297 -0.1737 -0.1468 -0.1704 -0.0744 -0.1009 -0.1164 -0.1484 -0.1760
S-307	In der zweiten Studie wurden ähnliche Ergebnisse beobachtet .
T-307	Similar results were seen in the second study .
H-307	-0.28288519382476807	Similar results were observed in the second study .
D-307	-0.28288519382476807	Similar results were observed in the second study .
P-307	-0.2935 -0.0830 -1.2248 -0.0923 -0.4681 -0.1283 -0.1462 -0.1175 -0.2525 -0.1316 -0.1740
S-303	Was waren die wesentlichen Bedenken des CHMP ?
T-303	What were the main concerns of the CHMP ?
H-303	-0.33798158168792725	What are the main concerns of the CHMP ?
D-303	-0.33798158168792725	What are the main concerns of the CHMP ?
P-303	-0.0944 -1.5881 -0.1269 -0.7706 -0.1656 -0.3177 -0.1584 -0.0916 -0.0389 -0.1808 -0.1848
S-125	Nur klare , farblose Lösungen verwenden .
T-125	Only a clear and colourless solution should be used .
H-125	-0.15559077262878418	Use only clear , colourless solutions .
D-125	-0.15559077262878418	Use only clear , colourless solutions .
P-125	-0.1192 -0.3297 -0.1737 -0.1468 -0.1704 -0.0744 -0.1009 -0.1164 -0.1484 -0.1760
S-280	- Dieses Arzneimittel wurde Ihnen verschrieben .
T-280	- This medicine has been prescribed for you .
H-280	-0.12020674347877502	- This medicine has been prescribed for you .
D-280	-0.12020674347877502	- This medicine has been prescribed for you .
P-280	-0.1748 -0.1027 -0.0420 -0.1779 -0.1087 -0.0119 -0.0568 -0.1607 -0.0854 -0.2096 -0.1918
S-175	Nur klare , farblose Lösungen verwenden .
T-175	Only a clear and colourless solution should be used .
H-175	-0.15559077262878418	Use only clear , colourless solutions .
D-175	-0.15559077262878418	Use only clear , colourless solutions .
P-175	-0.1192 -0.3297 -0.1737 -0.1468 -0.1704 -0.0744 -0.1009 -0.1164 -0.1484 -0.1760
S-200	Nur klare , farblose Lösungen verwenden .
T-200	Only a clear and colourless solution should be used .
H-200	-0.15559077262878418	Use only clear , colourless solutions .
D-200	-0.15559077262878418	Use only clear , colourless solutions .
P-200	-0.1192 -0.3297 -0.1737 -0.1468 -0.1704 -0.0744 -0.1009 -0.1164 -0.1484 -0.1760
S-226	Nur klare , farblose Lösungen verwenden .
T-226	Only a clear and colourless solution should be used .
H-226	-0.15559077262878418	Use only clear , colourless solutions .
D-226	-0.15559077262878418	Use only clear , colourless solutions .
P-226	-0.1192 -0.3297 -0.1737 -0.1468 -0.1704 -0.0744 -0.1009 -0.1164 -0.1484 -0.1760
S-281	Es darf nicht an Dritte weitergegeben werden .
T-281	Es darf nicht an Dritte weitergegeben werden . It may harm them , even
H-281	-0.6079968214035034	It should not be given to third parties .
D-281	-0.6079968214035034	It should not be given to third parties .
P-281	-0.0686 -1.2438 -0.1304 -0.1684 -1.3825 -0.1973 -1.8782 -0.6947 -0.1324 -0.1838
S-87	Gelegentlich Gelegentlich Gelegentlich
T-87	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-87	-1.0853029489517212	Uncommon Incidences
D-87	-1.0853029489517212	Uncommon Incidences
P-87	-1.6699 -0.0193 -3.8340 -0.8217 -0.5774 -0.1303 -0.5445
S-83	Erkrankungen des Gastrointestinaltrakts
T-83	5 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-83	-0.35842078924179077	Renal and gastro-intestinal disorders
D-83	-0.35842078924179077	Renal and gastro-intestinal disorders
P-83	-0.5243 -0.0980 -0.1298 -2.3960 -0.1381 -0.1804 -0.0326 -0.0379 -0.0441 -0.0649 -0.1141 -0.5407
S-288	Arzneimittel für Kinder unzugänglich aufbewahren .
T-288	Keep out of the reach and sight of children .
H-288	-0.12787504494190216	Keep out of the reach and sight of children .
D-288	-0.12787504494190216	Keep out of the reach and sight of children .
P-288	-0.0801 -0.1561 -0.1443 -0.1125 -0.0132 -0.1431 -0.1713 -0.1445 -0.1388 -0.1232 -0.1794
S-198	Das Transfersystem nicht aus der Verpackung
T-198	Do not remove the device from the package .
H-198	-0.5057743787765503	Keep the transfer system out of the package
D-198	-0.5057743787765503	Keep the transfer system out of the package
P-198	-1.9197 -0.8524 -0.0494 -0.0806 -0.3207 -0.1503 -0.1030 -0.8662 -0.2096
S-224	Das Transfersystem nicht aus der Verpackung
T-224	Do not remove the device from the package .
H-224	-0.5057743787765503	Keep the transfer system out of the package
D-224	-0.5057743787765503	Keep the transfer system out of the package
P-224	-1.9197 -0.8524 -0.0494 -0.0806 -0.3207 -0.1503 -0.1030 -0.8662 -0.2096
S-250	Vor der Anwendung Gebrauchsinformation lesen .
T-250	Vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-250	-0.2225363701581955	Read the leaflet before use .
D-250	-0.2225363701581955	Read the leaflet before use .
P-250	-0.0130 -0.2856 -0.8171 -0.0602 -0.1001 -0.1312 -0.2618 -0.1604 -0.1733
S-173	Das Transfersystem nicht aus der Verpackung
T-173	Do not remove the device from the package .
H-173	-0.5057743787765503	Keep the transfer system out of the package
D-173	-0.5057743787765503	Keep the transfer system out of the package
P-173	-1.9197 -0.8524 -0.0494 -0.0806 -0.3207 -0.1503 -0.1030 -0.8662 -0.2096
S-148	Das Transfersystem nicht aus der Verpackung
T-148	Do not remove the device from the package .
H-148	-0.5057743787765503	Keep the transfer system out of the package
D-148	-0.5057743787765503	Keep the transfer system out of the package
P-148	-1.9197 -0.8524 -0.0494 -0.0806 -0.3207 -0.1503 -0.1030 -0.8662 -0.2096
S-123	Das Transfersystem nicht aus der Verpackung
T-123	Do not remove the device from the package .
H-123	-0.5057743787765503	Keep the transfer system out of the package
D-123	-0.5057743787765503	Keep the transfer system out of the package
P-123	-1.9197 -0.8524 -0.0494 -0.0806 -0.3207 -0.1503 -0.1030 -0.8662 -0.2096
S-290	Diese Maßnahme hilft die Umwelt zu schützen .
T-290	These measures will help to protect the environment .
H-290	-0.15404416620731354	These measures will help to protect the environment .
D-290	-0.15404416620731354	These measures will help to protect the environment .
P-290	-0.1220 -0.2055 -0.2285 -0.0442 -0.1679 -0.2282 -0.1242 -0.1179 -0.1303 -0.1718
S-98	Das Transfersystem nicht aus der Verpackung
T-98	Do not remove the device from the package .
H-98	-0.5057743787765503	Keep the transfer system out of the package
D-98	-0.5057743787765503	Keep the transfer system out of the package
P-98	-1.9197 -0.8524 -0.0494 -0.0806 -0.3207 -0.1503 -0.1030 -0.8662 -0.2096
S-275	vor der Anwendung Gebrauchsinformation lesen .
T-275	vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-275	-0.284455806016922	Read the leaflet before use .
D-275	-0.284455806016922	Read the leaflet before use .
P-275	-0.4436 -0.3352 -0.7319 -0.0567 -0.1000 -0.1175 -0.4161 -0.1770 -0.1820
S-285	Sie sollten über frühe Anzeichen einer solchen
T-285	Sie sollten über frühe Anzeichen einer solchen These symptoms can constitute an early
H-285	-0.7763938307762146	You should be advised about early signs of such
D-285	-0.7763938307762146	You should be advised about early signs of such
P-285	-0.9578 -0.3703 -0.3528 -0.6569 -0.4468 -0.6729 -0.2704 -0.1558 -1.4152 -2.4650
S-111	0,85 0,43 0,43 0,43
T-111	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-111	-0.1935223788022995	0.85 0.43 0.43 0.43
D-111	-0.1935223788022995	0.85 0.43 0.43 0.43
P-111	-0.0648 -0.3670 -0.3281 -0.1176 -0.2288 -0.1216 -0.2444 -0.0955 -0.1740
S-136	0,85 0,43 0,43 0,43
T-136	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-136	-0.1935223788022995	0.85 0.43 0.43 0.43
D-136	-0.1935223788022995	0.85 0.43 0.43 0.43
P-136	-0.0648 -0.3670 -0.3281 -0.1176 -0.2288 -0.1216 -0.2444 -0.0955 -0.1740
S-161	0,85 0,43 0,43 0,43
T-161	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-161	-0.1935223788022995	0.85 0.43 0.43 0.43
D-161	-0.1935223788022995	0.85 0.43 0.43 0.43
P-161	-0.0648 -0.3670 -0.3281 -0.1176 -0.2288 -0.1216 -0.2444 -0.0955 -0.1740
S-186	0,85 0,43 0,43 0,43
T-186	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-186	-0.1935223788022995	0.85 0.43 0.43 0.43
D-186	-0.1935223788022995	0.85 0.43 0.43 0.43
P-186	-0.0648 -0.3670 -0.3281 -0.1176 -0.2288 -0.1216 -0.2444 -0.0955 -0.1740
S-212	0,85 0,43 0,43 0,43
T-212	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-212	-0.1935223788022995	0.85 0.43 0.43 0.43
D-212	-0.1935223788022995	0.85 0.43 0.43 0.43
P-212	-0.0648 -0.3670 -0.3281 -0.1176 -0.2288 -0.1216 -0.2444 -0.0955 -0.1740
S-209	Infektionen und parasitäre Erkrankungen
T-209	( % patients<<unk>> a Infections and infestations Blood and lymphatic system disorders
H-209	-0.3022248148918152	Infections and infestations
D-209	-0.3022248148918152	Infections and infestations
P-209	-0.0188 -0.0661 -0.1511 -0.2782 -0.3377 -0.5121 -0.7516
S-272	Für Kinder unzugänglich aufbewahren .
T-272	Keep out of the reach and sight of children .
H-272	-0.1325484663248062	Keep out of the reach and sight of children .
D-272	-0.1325484663248062	Keep out of the reach and sight of children .
P-272	-0.1360 -0.1756 -0.1460 -0.1129 -0.0154 -0.1412 -0.1089 -0.1468 -0.1625 -0.1339 -0.1789
S-256	Für Kinder unzugänglich aufbewahren .
T-256	Keep out of the reach and sight of children .
H-256	-0.1325484663248062	Keep out of the reach and sight of children .
D-256	-0.1325484663248062	Keep out of the reach and sight of children .
P-256	-0.1360 -0.1756 -0.1460 -0.1129 -0.0154 -0.1412 -0.1089 -0.1468 -0.1625 -0.1339 -0.1789
S-314	Erwachsene und Jugendliche ab 12 Jahren :
T-314	Adults and adolescents 12 years of age and over :
H-314	-0.5007839798927307	Adults and adolescents aged 12 years or over :
D-314	-0.5007839798927307	Adults and adolescents aged 12 years or over :
P-314	-0.2155 -0.7684 -0.1402 -0.4939 -0.0456 -0.5381 -0.8512 -0.5671 -0.5784 -1.0501 -0.8571 -0.2086 -0.1960
S-264	Für Kinder unzugänglich aufbewahren .
T-264	Keep out of the reach and sight of children .
H-264	-0.1325484663248062	Keep out of the reach and sight of children .
D-264	-0.1325484663248062	Keep out of the reach and sight of children .
P-264	-0.1360 -0.1756 -0.1460 -0.1129 -0.0154 -0.1412 -0.1089 -0.1468 -0.1625 -0.1339 -0.1789
S-239	Für Kinder unzugänglich aufbewahren .
T-239	Keep out of the reach and sight of children .
H-239	-0.1325484663248062	Keep out of the reach and sight of children .
D-239	-0.1325484663248062	Keep out of the reach and sight of children .
P-239	-0.1360 -0.1756 -0.1460 -0.1129 -0.0154 -0.1412 -0.1089 -0.1468 -0.1625 -0.1339 -0.1789
S-247	Für Kinder unzugänglich aufbewahren .
T-247	Keep out of the reach and sight of children .
H-247	-0.1325484663248062	Keep out of the reach and sight of children .
D-247	-0.1325484663248062	Keep out of the reach and sight of children .
P-247	-0.1360 -0.1756 -0.1460 -0.1129 -0.0154 -0.1412 -0.1089 -0.1468 -0.1625 -0.1339 -0.1789
S-231	Für Kinder unzugänglich aufbewahren .
T-231	Keep out of the reach and sight of children .
H-231	-0.1325484663248062	Keep out of the reach and sight of children .
D-231	-0.1325484663248062	Keep out of the reach and sight of children .
P-231	-0.1360 -0.1756 -0.1460 -0.1129 -0.0154 -0.1412 -0.1089 -0.1468 -0.1625 -0.1339 -0.1789
S-90	Pharmakotherapeutische Gruppe :
T-90	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-90	-0.28965333104133606	Pharmacotherapeutic group :
D-90	-0.28965333104133606	Pharmacotherapeutic group :
P-90	-1.1377 -0.0567 -0.1453 -0.1626 -0.0886 -0.1062 -0.2158 -0.3015 -0.3926
S-216	Pharmakotherapeutische Gruppe :
T-216	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-216	-0.28965333104133606	Pharmacotherapeutic group :
D-216	-0.28965333104133606	Pharmacotherapeutic group :
P-216	-1.1377 -0.0567 -0.1453 -0.1626 -0.0886 -0.1062 -0.2158 -0.3015 -0.3926
S-190	Pharmakotherapeutische Gruppe :
T-190	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-190	-0.28965333104133606	Pharmacotherapeutic group :
D-190	-0.28965333104133606	Pharmacotherapeutic group :
P-190	-1.1377 -0.0567 -0.1453 -0.1626 -0.0886 -0.1062 -0.2158 -0.3015 -0.3926
S-165	Pharmakotherapeutische Gruppe :
T-165	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-165	-0.28965333104133606	Pharmacotherapeutic group :
D-165	-0.28965333104133606	Pharmacotherapeutic group :
P-165	-1.1377 -0.0567 -0.1453 -0.1626 -0.0886 -0.1062 -0.2158 -0.3015 -0.3926
S-140	Pharmakotherapeutische Gruppe :
T-140	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-140	-0.28965333104133606	Pharmacotherapeutic group :
D-140	-0.28965333104133606	Pharmacotherapeutic group :
P-140	-1.1377 -0.0567 -0.1453 -0.1626 -0.0886 -0.1062 -0.2158 -0.3015 -0.3926
S-115	Pharmakotherapeutische Gruppe :
T-115	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-115	-0.28965333104133606	Pharmacotherapeutic group :
D-115	-0.28965333104133606	Pharmacotherapeutic group :
P-115	-1.1377 -0.0567 -0.1453 -0.1626 -0.0886 -0.1062 -0.2158 -0.3015 -0.3926
S-86	0,43 0,43 0,43
T-86	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-86	-0.2866467833518982	0.43 0.43 0.43 0.43
D-86	-0.2866467833518982	0.43 0.43 0.43 0.43
P-86	-0.0969 -0.1169 -0.2577 -0.1197 -0.2924 -0.0995 -1.2981 -0.0992 -0.1994
S-58	ADROVANCE
T-58	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-58	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
D-58	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
P-58	-0.9936 -0.0879 -0.1679 -0.0905 -0.0663 -2.6913 -0.2227 -0.1446 -0.0265 -0.1149 -0.1137 -0.0135 -0.0054 -0.1771 -2.2281
S-57	Alendronat
T-57	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-57	-0.2644961178302765	Alendronate
D-57	-0.2644961178302765	Alendronate
P-57	-0.3251 -0.1463 -0.0983 -0.0345 -0.7183
S-141	PK-Parameter
T-141	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-141	-0.6369642019271851	Parameters of the PK
D-141	-0.6369642019271851	Parameters of the PK
P-141	-1.0522 -0.1431 -0.1249 -0.3390 -0.9710 -1.9109 -0.2980 -0.2567
S-40	ADROVANCE
T-40	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-40	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
D-40	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
P-40	-0.9936 -0.0879 -0.1679 -0.0905 -0.0663 -2.6913 -0.2227 -0.1446 -0.0265 -0.1149 -0.1137 -0.0135 -0.0054 -0.1771 -2.2281
S-56	ADROVANCE
T-56	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-56	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
D-56	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
P-56	-0.9936 -0.0879 -0.1679 -0.0905 -0.0663 -2.6913 -0.2227 -0.1446 -0.0265 -0.1149 -0.1137 -0.0135 -0.0054 -0.1771 -2.2281
S-38	Alendronat
T-38	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-38	-0.2644961178302765	Alendronate
D-38	-0.2644961178302765	Alendronate
P-38	-0.3251 -0.1463 -0.0983 -0.0345 -0.7183
S-91	PK-Parameter
T-91	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-91	-0.6369642019271851	Parameters of the PK
D-91	-0.6369642019271851	Parameters of the PK
P-91	-1.0522 -0.1431 -0.1249 -0.3390 -0.9710 -1.9109 -0.2980 -0.2567
S-37	ADROVANCE
T-37	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-37	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
D-37	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
P-37	-0.9936 -0.0879 -0.1679 -0.0905 -0.0663 -2.6913 -0.2227 -0.1446 -0.0265 -0.1149 -0.1137 -0.0135 -0.0054 -0.1771 -2.2281
S-166	PK-Parameter
T-166	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-166	-0.6369642019271851	Parameters of the PK
D-166	-0.6369642019271851	Parameters of the PK
P-166	-1.0522 -0.1431 -0.1249 -0.3390 -0.9710 -1.9109 -0.2980 -0.2567
S-191	PK-Parameter
T-191	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-191	-0.6369642019271851	Parameters of the PK
D-191	-0.6369642019271851	Parameters of the PK
P-191	-1.0522 -0.1431 -0.1249 -0.3390 -0.9710 -1.9109 -0.2980 -0.2567
S-116	PK-Parameter
T-116	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-116	-0.6369642019271851	Parameters of the PK
D-116	-0.6369642019271851	Parameters of the PK
P-116	-1.0522 -0.1431 -0.1249 -0.3390 -0.9710 -1.9109 -0.2980 -0.2567
S-39	ADROVANCE
T-39	Your doctor has prescribed ADROVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency .
H-39	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
D-39	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
P-39	-0.9936 -0.0879 -0.1679 -0.0905 -0.0663 -2.6913 -0.2227 -0.1446 -0.0265 -0.1149 -0.1137 -0.0135 -0.0054 -0.1771 -2.2281
S-217	PK-Parameter
T-217	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-217	-0.6369642019271851	Parameters of the PK
D-217	-0.6369642019271851	Parameters of the PK
P-217	-1.0522 -0.1431 -0.1249 -0.3390 -0.9710 -1.9109 -0.2980 -0.2567
S-309	2,5 mg / 120 mg
T-309	2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg
H-309	-0.15288065373897552	2.5 mg / 120 mg
D-309	-0.15288065373897552	2.5 mg / 120 mg
P-309	-0.3168 -0.0678 -0.1461 -0.1303 -0.0792 -0.1770
S-60	ADROVANCE
T-60	47 5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-60	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
D-60	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
P-60	-0.9936 -0.0879 -0.1679 -0.0905 -0.0663 -2.6913 -0.2227 -0.1446 -0.0265 -0.1149 -0.1137 -0.0135 -0.0054 -0.1771 -2.2281
S-45	ADROVANCE
T-45	5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-45	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
D-45	-0.4762638211250305	ADROVANCE Ear and labyrinth disorders
P-45	-0.9936 -0.0879 -0.1679 -0.0905 -0.0663 -2.6913 -0.2227 -0.1446 -0.0265 -0.1149 -0.1137 -0.0135 -0.0054 -0.1771 -2.2281
S-211	2 1 1 1
T-211	2 1 1 1 2 2 1 1 3 1
H-211	-0.6864413619041443	2 1 1 1
D-211	-0.6864413619041443	2 1 1 1
P-211	-2.4269 -0.1916 -0.1374 -0.2443 -0.4319
S-135	2 1 1 1
T-135	2 1 1 1 2 2 1 1 3 1
H-135	-0.6864413619041443	2 1 1 1
D-135	-0.6864413619041443	2 1 1 1
P-135	-2.4269 -0.1916 -0.1374 -0.2443 -0.4319
S-110	2 1 1 1
T-110	2 1 1 1 2 2 1 1 3 1
H-110	-0.6864413619041443	2 1 1 1
D-110	-0.6864413619041443	2 1 1 1
P-110	-2.4269 -0.1916 -0.1374 -0.2443 -0.4319
S-185	2 1 1 1
T-185	2 1 1 1 2 2 1 1 3 1
H-185	-0.6864413619041443	2 1 1 1
D-185	-0.6864413619041443	2 1 1 1
P-185	-2.4269 -0.1916 -0.1374 -0.2443 -0.4319
S-16	32 % ) .
T-16	32 % , respectively ) , through week 15.
H-16	-0.2933247983455658	It has been proposed that aripiprazole s efficacy in schizophrenia , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I , Bipolar I , Bipolar I
D-16	-0.2933247983455658	It has been proposed that aripiprazole s efficacy in schizophrenia , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I , Bipolar I , Bipolar I
P-16	-2.3569 -1.5291 -0.8699 -0.8502 -0.2035 -0.2065 -0.4160 -0.0068 -0.1034 -0.0474 -0.0065 -0.0004 -0.1180 -0.0458 -0.0956 -1.4956 -0.0161 -0.0184 -0.0180 -0.0932 -2.0959 -0.0078 -0.0055 -0.0749 -0.0172 -0.0031 -0.0192 -1.1391 -0.0142 -0.0007 -0.0768 -0.0242 -0.0034 -0.0158 -1.3636 -0.0326 -0.0008 -0.0801 -0.0459 -0.0031 -0.0175 -1.1859 -0.0788 -0.0007 -0.0816 -0.0567 -0.0031 -0.0190 -0.6877 -0.2082 -0.0007 -0.0840 -0.0731 -0.0030 -0.0158 -0.4347 -0.3691 -0.0006 -0.0872 -0.0803 -0.0042 -0.0193 -0.3667 -0.6703 -0.0006 -0.0812 -0.0974 -0.0047 -0.0193 -0.3386 -0.9281 -0.0006 -0.0780 -0.1040 -0.0029 -0.0187 -0.3575 -1.0315 -0.0005 -0.0769 -0.0878 -0.0021 -0.0139 -0.3445 -0.8634 -0.0008 -0.0806 -0.0971 -0.0028 -0.0144 -0.3938 -0.6533 -0.0008 -0.0801 -0.1098 -0.0612 -0.0171 -0.3370 -0.7217 -0.0007 -0.0919 -0.1102 -0.2627 -0.0192 -0.3270 -0.7783 -0.0009 -0.0906 -0.1294 -0.1886 -0.0301 -0.2769 -0.8680 -0.0010 -0.0878 -0.1219 -0.4153 -0.8888 -0.0008 -0.0833 -0.1207 -1.1043 -0.9627 -0.0008 -0.0974 -0.1299 -4.9708
S-48	Informieren Sie
T-48	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-48	-0.47506314516067505	Be sure to tell your doctor or pharmacist if you are being treated for epilepsy or if you have recently had suicidal thoughts ina
D-48	-0.47506314516067505	Be sure to tell your doctor or pharmacist if you are being treated for epilepsy or if you have recently had suicidal thoughts ina
P-48	-2.6195 -0.0312 -0.1530 -0.4880 -0.1523 -0.0625 -0.8076 -0.0563 -0.0237 -0.6642 -0.1009 -0.9730 -1.4882 -0.0577 -0.1083 -0.1135 -0.0173 -0.1584 -0.0157 -0.1454 -2.2813 -0.3860 -0.8602 -0.0837 -0.8140 -0.3926 -0.0202 -0.1757 -0.0302 -0.9714
S-160	2 1 1 1
T-160	2 1 1 1 2 2 1 1 3 1
H-160	-0.6864413619041443	2 1 1 1
D-160	-0.6864413619041443	2 1 1 1
P-160	-2.4269 -0.1916 -0.1374 -0.2443 -0.4319
S-313	14 Tabletten
T-313	2 tablets 4 tablets 7 tablets 10 tablets 14 tablets 20 tablets
H-313	-0.4928579032421112	EU/ 1/ 14 tablets
D-313	-0.4928579032421112	EU/ 1/ 14 tablets
P-313	-0.0600 -0.5417 -0.0564 -0.1957 -2.0423 -0.5942 -0.0814 -0.3711
S-63	Informieren Sie
T-63	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-63	-0.47506314516067505	Be sure to tell your doctor or pharmacist if you are being treated for epilepsy or if you have recently had suicidal thoughts ina
D-63	-0.47506314516067505	Be sure to tell your doctor or pharmacist if you are being treated for epilepsy or if you have recently had suicidal thoughts ina
P-63	-2.6195 -0.0312 -0.1530 -0.4880 -0.1523 -0.0625 -0.8076 -0.0563 -0.0237 -0.6642 -0.1009 -0.9730 -1.4882 -0.0577 -0.1083 -0.1135 -0.0173 -0.1584 -0.0157 -0.1454 -2.2813 -0.3860 -0.8602 -0.0837 -0.8140 -0.3926 -0.0202 -0.1757 -0.0302 -0.9714
S-84	Verabreichungsort
T-84	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-84	-0.5557116866111755	Administration sites
D-84	-0.5557116866111755	Administration sites
P-84	-0.5467 -0.8223 -0.2982
S-29	32 % ) .
T-29	32 % , respectively ) , through week 15.
H-29	-0.2933247983455658	It has been proposed that aripiprazole s efficacy in schizophrenia , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I , Bipolar I , Bipolar I
D-29	-0.2933247983455658	It has been proposed that aripiprazole s efficacy in schizophrenia , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I Disorder , Bipolar I , Bipolar I , Bipolar I
P-29	-2.3569 -1.5291 -0.8699 -0.8502 -0.2035 -0.2065 -0.4160 -0.0068 -0.1034 -0.0474 -0.0065 -0.0004 -0.1180 -0.0458 -0.0956 -1.4956 -0.0161 -0.0184 -0.0180 -0.0932 -2.0959 -0.0078 -0.0055 -0.0749 -0.0172 -0.0031 -0.0192 -1.1391 -0.0142 -0.0007 -0.0768 -0.0242 -0.0034 -0.0158 -1.3636 -0.0326 -0.0008 -0.0801 -0.0459 -0.0031 -0.0175 -1.1859 -0.0788 -0.0007 -0.0816 -0.0567 -0.0031 -0.0190 -0.6877 -0.2082 -0.0007 -0.0840 -0.0731 -0.0030 -0.0158 -0.4347 -0.3691 -0.0006 -0.0872 -0.0803 -0.0042 -0.0193 -0.3667 -0.6703 -0.0006 -0.0812 -0.0974 -0.0047 -0.0193 -0.3386 -0.9281 -0.0006 -0.0780 -0.1040 -0.0029 -0.0187 -0.3575 -1.0315 -0.0005 -0.0769 -0.0878 -0.0021 -0.0139 -0.3445 -0.8634 -0.0008 -0.0806 -0.0971 -0.0028 -0.0144 -0.3938 -0.6533 -0.0008 -0.0801 -0.1098 -0.0612 -0.0171 -0.3370 -0.7217 -0.0007 -0.0919 -0.1102 -0.2627 -0.0192 -0.3270 -0.7783 -0.0009 -0.0906 -0.1294 -0.1886 -0.0301 -0.2769 -0.8680 -0.0010 -0.0878 -0.1219 -0.4153 -0.8888 -0.0008 -0.0833 -0.1207 -1.1043 -0.9627 -0.0008 -0.0974 -0.1299 -4.9708
S-62	Gelegentlich
T-62	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-62	-1.3643155097961426	Uncommon side effects
D-62	-1.3643155097961426	Uncommon side effects
P-62	-2.8107 -0.0155 -2.4155 -0.1172 -1.4627
S-61	Häufig :
T-61	The following terms are used to describe how often side effects have been reported :
H-61	-0.6711877584457397	Common :
D-61	-0.6711877584457397	Common :
P-61	-1.8868 -0.1083 -0.2081 -0.4817
S-47	Gelegentlich
T-47	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-47	-1.3643155097961426	Uncommon side effects
D-47	-1.3643155097961426	Uncommon side effects
P-47	-2.8107 -0.0155 -2.4155 -0.1172 -1.4627
S-85	1 1 1
T-85	2 1 1 1 2 2 1 1 3 1
H-85	-0.39707180857658386	Luxembourg/ Luxemburg sanofi-aventis Belgium Tél/ Tel : <unk> 32 1 1 1 1
D-85	-0.39707180857658386	Luxembourg/ Luxemburg sanofi-aventis Belgium Tél/ Tel : <unk> 32 1 1 1 1
P-85	-5.3105 -0.0666 -0.0073 -0.0481 -0.0451 -0.0104 -0.0073 -0.0252 -0.0001 -0.0017 -0.0003 -0.0589 -0.0746 -0.0239 -0.0029 -0.0009 -0.0161 -0.0016 -0.1017 -0.0029 -0.1658 -1.8814 -0.1255 -0.1609 -0.4667 -1.7176
S-51	Tel . :
T-51	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-51	-0.7174834609031677	Tel : <unk> 353 ( 0 ) 1 403 56 lp
D-51	-0.7174834609031677	Tel : <unk> 353 ( 0 ) 1 403 56 lp
P-51	-0.0325 -0.2448 -0.0038 -0.3090 -0.4668 -0.1409 -0.3960 -0.1339 -0.7929 -1.5767 -2.4754 -2.8022 -0.6960 -0.0481 -0.6431
S-66	Tel . :
T-66	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-66	-0.7174834609031677	Tel : <unk> 353 ( 0 ) 1 403 56 lp
D-66	-0.7174834609031677	Tel : <unk> 353 ( 0 ) 1 403 56 lp
P-66	-0.0325 -0.2448 -0.0038 -0.3090 -0.4668 -0.1409 -0.3960 -0.1339 -0.7929 -1.5767 -2.4754 -2.8022 -0.6960 -0.0481 -0.6431
S-55	Tel : +
T-55	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-55	-1.2048823833465576	Tel : + 1 ( 0 ) 1 403 53 00 lp
D-55	-1.2048823833465576	Tel : + 1 ( 0 ) 1 403 53 00 lp
P-55	-0.0064 -0.1720 -0.1809 -1.3240 -2.7091 -0.5323 -0.1201 -1.2734 -2.2514 -3.0744 -3.6378 -0.9050 -0.3193 -0.0558 -1.5113
S-70	Tel : +
T-70	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-70	-1.2048823833465576	Tel : + 1 ( 0 ) 1 403 53 00 lp
D-70	-1.2048823833465576	Tel : + 1 ( 0 ) 1 403 53 00 lp
P-70	-0.0064 -0.1720 -0.1809 -1.3240 -2.7091 -0.5323 -0.1201 -1.2734 -2.2514 -3.0744 -3.6378 -0.9050 -0.3193 -0.0558 -1.5113
S-46	Häufig :
T-46	The following terms are used to describe how often side effects have been reported :
H-46	-0.6711877584457397	Common :
D-46	-0.6711877584457397	Common :
P-46	-1.8868 -0.1083 -0.2081 -0.4817
S-68	Tel :
T-68	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-68	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
D-68	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
P-68	-0.0188 -0.1710 -0.0067 -0.3427 -0.4218 -0.1359 -0.3391 -0.1402 -0.8368 -1.4349 -2.4471 -2.7408 -0.6926 -0.0549 -0.8299
S-69	Tel :
T-69	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-69	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
D-69	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
P-69	-0.0188 -0.1710 -0.0067 -0.3427 -0.4218 -0.1359 -0.3391 -0.1402 -0.8368 -1.4349 -2.4471 -2.7408 -0.6926 -0.0549 -0.8299
S-53	Tel :
T-53	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-53	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
D-53	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
P-53	-0.0188 -0.1710 -0.0067 -0.3427 -0.4218 -0.1359 -0.3391 -0.1402 -0.8368 -1.4349 -2.4471 -2.7408 -0.6926 -0.0549 -0.8299
S-54	Tel :
T-54	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-54	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
D-54	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
P-54	-0.0188 -0.1710 -0.0067 -0.3427 -0.4218 -0.1359 -0.3391 -0.1402 -0.8368 -1.4349 -2.4471 -2.7408 -0.6926 -0.0549 -0.8299
S-52	Tel :
T-52	Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-52	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
D-52	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
P-52	-0.0188 -0.1710 -0.0067 -0.3427 -0.4218 -0.1359 -0.3391 -0.1402 -0.8368 -1.4349 -2.4471 -2.7408 -0.6926 -0.0549 -0.8299
S-67	Tel :
T-67	50 Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-67	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
D-67	-0.7075508832931519	Tel : <unk> 353 ( 0 ) 1 403 56 lp
P-67	-0.0188 -0.1710 -0.0067 -0.3427 -0.4218 -0.1359 -0.3391 -0.1402 -0.8368 -1.4349 -2.4471 -2.7408 -0.6926 -0.0549 -0.8299
S-82	0,43
T-82	Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-82	-0.7092714309692383	0.43 Magnesium stearate
D-82	-0.7092714309692383	0.43 Magnesium stearate
P-82	-0.4132 -0.1366 -4.4247 -1.4706 -0.0315 -0.2501 -0.0021 -0.1255 -0.0090 -0.2294
S-50	Die
T-50	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-50	-0.3288906216621399	or Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa .
D-50	-0.3288906216621399	or Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa .
P-50	-4.7353 -0.7749 -0.0940 -0.0282 -0.2367 -0.9353 -0.0210 -0.0734 -0.0909 -0.1497 -0.0668 -0.1884 -0.0018 -0.0848 -0.0032 -0.2300 -0.0074 -0.0507 -0.0228 -0.1458 -0.0059 -0.2007 -0.1436 -0.0120 -0.1767 -0.1693 -0.0030 -0.0014 -0.1100 -0.1326 -0.0038 -0.0162 -0.1371 -0.0069 -0.1311 -2.6486
S-43	(
T-43	40 3 ) Do not lie down stay fully upright ( sitting , standing or walking ) for at least 30 minutes after swallowing the tablet .
H-43	-0.23612023890018463	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
D-43	-0.23612023890018463	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
P-43	-0.9982 -0.8845 -0.4454 -1.7614 -0.1950 -0.0905 -0.0712 -0.0131 -0.0054 -0.0094 -0.0006 -0.0152 -0.0099 -0.0490 -0.0181 -0.1442 -0.1491 -0.0175 -0.3445 -0.0044 -0.1011 -0.2021 -0.9452 -0.0011 -0.0006 -0.0508 -0.0036 -0.0383 -0.1038 -0.0007 -0.0177 -0.0008 -1.0255 -0.3103
S-317	2
T-317	2 a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke .
H-317	-0.25726765394210815	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
D-317	-0.25726765394210815	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
P-317	-2.1846 -1.6812 -0.4610 -1.0268 -0.1989 -0.0782 -0.0720 -0.0145 -0.0050 -0.0096 -0.0006 -0.0163 -0.0078 -0.0542 -0.0208 -0.1443 -0.1518 -0.0219 -0.3646 -0.0037 -0.0981 -0.1700 -0.7404 -0.0011 -0.0004 -0.0449 -0.0032 -0.0415 -0.1062 -0.0006 -0.0222 -0.0014 -0.7413 -0.2584
S-44	(
T-44	4 ) Do not take ADROVANCE at bedtime or before getting up for the day .
H-44	-0.23612023890018463	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
D-44	-0.23612023890018463	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
P-44	-0.9982 -0.8845 -0.4454 -1.7614 -0.1950 -0.0905 -0.0712 -0.0131 -0.0054 -0.0094 -0.0006 -0.0152 -0.0099 -0.0490 -0.0181 -0.1442 -0.1491 -0.0175 -0.3445 -0.0044 -0.1011 -0.2021 -0.9452 -0.0011 -0.0006 -0.0508 -0.0036 -0.0383 -0.1038 -0.0007 -0.0177 -0.0008 -1.0255 -0.3103
S-65	Die
T-65	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-65	-0.3288906216621399	or Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa .
D-65	-0.3288906216621399	or Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa .
P-65	-4.7353 -0.7749 -0.0940 -0.0282 -0.2367 -0.9353 -0.0210 -0.0734 -0.0909 -0.1497 -0.0668 -0.1884 -0.0018 -0.0848 -0.0032 -0.2300 -0.0074 -0.0507 -0.0228 -0.1458 -0.0059 -0.2007 -0.1436 -0.0120 -0.1767 -0.1693 -0.0030 -0.0014 -0.1100 -0.1326 -0.0038 -0.0162 -0.1371 -0.0069 -0.1311 -2.6486
S-64	Das
T-64	The expiry date refers to the last day of that month .
H-64	-0.34050795435905457	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
D-64	-0.34050795435905457	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
P-64	-4.2776 -2.6915 -0.6399 -0.9054 -0.2281 -0.1013 -0.0665 -0.0168 -0.0046 -0.0114 -0.0009 -0.0144 -0.0101 -0.0570 -0.0150 -0.1438 -0.1470 -0.0181 -0.3360 -0.0029 -0.0985 -0.2401 -0.6913 -0.0012 -0.0004 -0.0529 -0.0044 -0.0414 -0.0998 -0.0008 -0.0248 -0.0016 -0.3870 -0.2444
S-35	2.
T-35	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-35	-0.24547447264194489	or Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa .
D-35	-0.24547447264194489	or Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa .
P-35	-2.8122 -0.3486 -0.0951 -0.0276 -0.2327 -0.9857 -0.0316 -0.0741 -0.0881 -0.1464 -0.0658 -0.2011 -0.0027 -0.0890 -0.0030 -0.2107 -0.0050 -0.0643 -0.0212 -0.1426 -0.0046 -0.1946 -0.1599 -0.0108 -0.1813 -0.1702 -0.0031 -0.0014 -0.1102 -0.1333 -0.0065 -0.0097 -0.1408 -0.0106 -0.1370 -1.9155
S-36	2.
T-36	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-36	-0.24547447264194489	or Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa .
D-36	-0.24547447264194489	or Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <unk> www . emea . europa .
P-36	-2.8122 -0.3486 -0.0951 -0.0276 -0.2327 -0.9857 -0.0316 -0.0741 -0.0881 -0.1464 -0.0658 -0.2011 -0.0027 -0.0890 -0.0030 -0.2107 -0.0050 -0.0643 -0.0212 -0.1426 -0.0046 -0.1946 -0.1599 -0.0108 -0.1813 -0.1702 -0.0031 -0.0014 -0.1102 -0.1333 -0.0065 -0.0097 -0.1408 -0.0106 -0.1370 -1.9155
S-41	Sie
T-41	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-41	-0.3060305416584015	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
D-41	-0.3060305416584015	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
P-41	-3.5320 -1.4096 -0.2081 -1.6457 -0.2445 -0.1258 -0.0592 -0.0165 -0.0047 -0.0096 -0.0009 -0.0145 -0.0096 -0.0555 -0.0197 -0.1462 -0.1382 -0.0145 -0.2671 -0.0037 -0.0952 -0.1323 -0.9824 -0.0012 -0.0004 -0.0521 -0.0038 -0.0407 -0.0956 -0.0005 -0.0174 -0.0020 -0.7958 -0.2600
S-59	Sie
T-59	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-59	-0.3060305416584015	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
D-59	-0.3060305416584015	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
P-59	-3.5320 -1.4096 -0.2081 -1.6457 -0.2445 -0.1258 -0.0592 -0.0165 -0.0047 -0.0096 -0.0009 -0.0145 -0.0096 -0.0555 -0.0197 -0.1462 -0.1382 -0.0145 -0.2671 -0.0037 -0.0952 -0.1323 -0.9824 -0.0012 -0.0004 -0.0521 -0.0038 -0.0407 -0.0956 -0.0005 -0.0174 -0.0020 -0.7958 -0.2600
S-42	(
T-42	2 ) After getting up for the day and before taking any food , drink , or other medicine , swallow your ADROVANCE tablet with a full glass of water only ( not mineral water ) ( not less than 200 ml or 7 fl . oz . ) . Do not take with mineral water ( still or sparkling ) . Do not take with coffee or tea . Do not take with juice or milk .
H-42	-0.23612023890018463	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
D-42	-0.23612023890018463	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
P-42	-0.9982 -0.8845 -0.4454 -1.7614 -0.1950 -0.0905 -0.0712 -0.0131 -0.0054 -0.0094 -0.0006 -0.0152 -0.0099 -0.0490 -0.0181 -0.1442 -0.1491 -0.0175 -0.3445 -0.0044 -0.1011 -0.2021 -0.9452 -0.0011 -0.0006 -0.0508 -0.0036 -0.0383 -0.1038 -0.0007 -0.0177 -0.0008 -1.0255 -0.3103
S-49	Das
T-49	The expiry date refers to the last day of that month .
H-49	-0.34050795435905457	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
D-49	-0.34050795435905457	ge If you forget to take ACOMPLIA Take it as soon as you remember but do not take a double dose to make up for any forgotten dose .
P-49	-4.2776 -2.6915 -0.6399 -0.9054 -0.2281 -0.1013 -0.0665 -0.0168 -0.0046 -0.0114 -0.0009 -0.0144 -0.0101 -0.0570 -0.0150 -0.1438 -0.1470 -0.0181 -0.3360 -0.0029 -0.0985 -0.2401 -0.6913 -0.0012 -0.0004 -0.0529 -0.0044 -0.0414 -0.0998 -0.0008 -0.0248 -0.0016 -0.3870 -0.2444
S-108	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-108	Animal reproduction studies have not been conducted with factor VIII .
H-108	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
D-108	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
P-108	-0.2607 -0.0537 -0.1133 -0.2504 -0.0359 -0.7351 -0.1069 -0.1069 -0.4227 -0.3263 -0.3118 -0.1876 -0.0798 -0.7104 -0.1895
S-77	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-77	More extensive haemarthrosis , muscle bleeding or haematoma .
H-77	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
D-77	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
P-77	-2.4806 -0.2544 -0.0554 -0.0594 -0.3587 -0.0068 -0.0138 -0.1662 -0.1626 -0.8065 -0.8026 -0.0049 -0.0057 -0.1399 -0.5581 -0.1730 -0.0410 -0.1312 -0.0591 -0.1424 -0.1785
S-204	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-204	More extensive haemarthrosis , muscle bleeding or haematoma .
H-204	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
D-204	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
P-204	-2.4806 -0.2544 -0.0554 -0.0594 -0.3587 -0.0068 -0.0138 -0.1662 -0.1626 -0.8065 -0.8026 -0.0049 -0.0057 -0.1399 -0.5581 -0.1730 -0.0410 -0.1312 -0.0591 -0.1424 -0.1785
S-133	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-133	Animal reproduction studies have not been conducted with factor VIII .
H-133	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
D-133	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
P-133	-0.2607 -0.0537 -0.1133 -0.2504 -0.0359 -0.7351 -0.1069 -0.1069 -0.4227 -0.3263 -0.3118 -0.1876 -0.0798 -0.7104 -0.1895
S-158	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-158	Animal reproduction studies have not been conducted with factor VIII .
H-158	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
D-158	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
P-158	-0.2607 -0.0537 -0.1133 -0.2504 -0.0359 -0.7351 -0.1069 -0.1069 -0.4227 -0.3263 -0.3118 -0.1876 -0.0798 -0.7104 -0.1895
S-183	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-183	Animal reproduction studies have not been conducted with factor VIII .
H-183	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
D-183	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
P-183	-0.2607 -0.0537 -0.1133 -0.2504 -0.0359 -0.7351 -0.1069 -0.1069 -0.4227 -0.3263 -0.3118 -0.1876 -0.0798 -0.7104 -0.1895
S-74	1 Durchstechflasche + 1 Durchstechflasche + Gerät zur Rekonstitution
T-74	1 vial + 1 vial + reconstitution device
H-74	-0.18052786588668823	1 vial + 1 vial + 1 vial for reconstitution
D-74	-0.18052786588668823	1 vial + 1 vial + 1 vial for reconstitution
P-74	-0.1149 -0.2216 -0.1121 -0.1411 -0.1481 -0.1417 -0.1154 -0.1736 -0.1125 -0.7344 -0.1169 -0.1743 -0.1383 -0.1093 -0.1538
S-293	eská republika Baxter Czech spol.s.r.o .
T-293	eská republika Baxter Czech spol . s. r. o.
H-293	-0.35984328389167786	eská republika Baxter Czech spol. s. r. o. o.
D-293	-0.35984328389167786	eská republika Baxter Czech spol. s. r. o. o.
P-293	-0.0175 -0.1685 -0.0404 -0.0518 -0.0535 -1.0141 -0.1238 -0.1823 -0.4375 -0.0602 -0.1950 -1.1638 -0.0876 -0.0256 -0.3107 -1.0255 -1.1595
S-208	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-208	Animal reproduction studies have not been conducted with factor VIII .
H-208	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
D-208	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
P-208	-0.2607 -0.0537 -0.1133 -0.2504 -0.0359 -0.7351 -0.1069 -0.1069 -0.4227 -0.3263 -0.3118 -0.1876 -0.0798 -0.7104 -0.1895
S-104	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-104	More extensive haemarthrosis , muscle bleeding or haematoma .
H-104	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
D-104	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
P-104	-2.4806 -0.2544 -0.0554 -0.0594 -0.3587 -0.0068 -0.0138 -0.1662 -0.1626 -0.8065 -0.8026 -0.0049 -0.0057 -0.1399 -0.5581 -0.1730 -0.0410 -0.1312 -0.0591 -0.1424 -0.1785
S-129	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-129	More extensive haemarthrosis , muscle bleeding or haematoma .
H-129	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
D-129	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
P-129	-2.4806 -0.2544 -0.0554 -0.0594 -0.3587 -0.0068 -0.0138 -0.1662 -0.1626 -0.8065 -0.8026 -0.0049 -0.0057 -0.1399 -0.5581 -0.1730 -0.0410 -0.1312 -0.0591 -0.1424 -0.1785
S-154	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-154	More extensive haemarthrosis , muscle bleeding or haematoma .
H-154	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
D-154	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
P-154	-2.4806 -0.2544 -0.0554 -0.0594 -0.3587 -0.0068 -0.0138 -0.1662 -0.1626 -0.8065 -0.8026 -0.0049 -0.0057 -0.1399 -0.5581 -0.1730 -0.0410 -0.1312 -0.0591 -0.1424 -0.1785
S-179	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-179	More extensive haemarthrosis , muscle bleeding or haematoma .
H-179	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
D-179	-0.31432199478149414	more pronounced joint haemorrhage , muscle haemorrhage or haematoma .
P-179	-2.4806 -0.2544 -0.0554 -0.0594 -0.3587 -0.0068 -0.0138 -0.1662 -0.1626 -0.8065 -0.8026 -0.0049 -0.0057 -0.1399 -0.5581 -0.1730 -0.0410 -0.1312 -0.0591 -0.1424 -0.1785
S-81	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-81	Animal reproduction studies have not been conducted with factor VIII .
H-81	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
D-81	-0.2593926787376404	Animal reproductive studies have not been performed with factor VIII .
P-81	-0.2607 -0.0537 -0.1133 -0.2504 -0.0359 -0.7351 -0.1069 -0.1069 -0.4227 -0.3263 -0.3118 -0.1876 -0.0798 -0.7104 -0.1895
S-144	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-144	For administration the use of a luer-lock syringe is required .
H-144	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
D-144	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
P-144	-0.7737 -1.1503 -0.3496 -1.7027 -0.5482 -0.9115 -0.1685 -0.0453 -0.0424 -0.1405 -0.6363 -0.2519 -0.3662 -0.1487 -0.1745
S-220	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-220	For administration the use of a luer-lock syringe is required .
H-220	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
D-220	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
P-220	-0.7737 -1.1503 -0.3496 -1.7027 -0.5482 -0.9115 -0.1685 -0.0453 -0.0424 -0.1405 -0.6363 -0.2519 -0.3662 -0.1487 -0.1745
S-93	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-93	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-93	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
D-93	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
P-93	-0.1036 -0.3185 -0.2446 -0.1569 -0.1210 -0.8413 -0.9765 -0.0836 -0.1732 -0.1466 -0.0886 -0.0591 -0.1569 -0.2028 -0.1559 -0.1650
S-169	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-169	For administration the use of a luer-lock syringe is required .
H-169	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
D-169	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
P-169	-0.7737 -1.1503 -0.3496 -1.7027 -0.5482 -0.9115 -0.1685 -0.0453 -0.0424 -0.1405 -0.6363 -0.2519 -0.3662 -0.1487 -0.1745
S-143	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-143	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-143	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
D-143	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
P-143	-0.1036 -0.3185 -0.2446 -0.1569 -0.1210 -0.8413 -0.9765 -0.0836 -0.1732 -0.1466 -0.0886 -0.0591 -0.1569 -0.2028 -0.1559 -0.1650
S-119	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-119	For administration the use of a luer-lock syringe is required .
H-119	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
D-119	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
P-119	-0.7737 -1.1503 -0.3496 -1.7027 -0.5482 -0.9115 -0.1685 -0.0453 -0.0424 -0.1405 -0.6363 -0.2519 -0.3662 -0.1487 -0.1745
S-94	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-94	For administration the use of a luer-lock syringe is required .
H-94	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
D-94	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
P-94	-0.7737 -1.1503 -0.3496 -1.7027 -0.5482 -0.9115 -0.1685 -0.0453 -0.0424 -0.1405 -0.6363 -0.2519 -0.3662 -0.1487 -0.1745
S-301	Li-Fraumeni-Krebs kann in vielen Teilen des Körpers auftreten .
T-301	People who have this mutation are more likely to develop cancer .
H-301	-0.4395005702972412	Li-woman-like cancer can occur in many parts of the body .
D-301	-0.4395005702972412	Li-woman-like cancer can occur in many parts of the body .
P-301	-0.4167 -0.2578 -0.7154 -1.4488 -0.2440 -0.8878 -0.7020 -0.3378 -0.1599 -0.1470 -1.0567 -0.3517 -0.1446 -0.1345 -0.1261 -0.1541 -0.1867
S-228	Name und Anschrift des Herstellers des Wirkstoffs biologischen Ursprungs
T-228	Name and address of the manufacturer of the biological active substance
H-228	-0.18433672189712524	Name and address of the manufacturer of the biological active substance
D-228	-0.18433672189712524	Name and address of the manufacturer of the biological active substance
P-228	-0.3907 -0.1493 -0.1706 -0.1545 -0.1226 -0.2882 -0.1317 -0.1119 -0.0680 -0.2055 -0.2170 -0.1029 -0.2836
S-130	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-130	Method of administration ADVATE should be administered via the intravenous route .
H-130	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
D-130	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
P-130	-3.7308 -0.0119 -0.0096 -0.1823 -0.0309 -0.1600 -0.1934 -0.0669 -0.1389 -0.7407 -0.2678 -0.1681 -0.8657 -0.0771 -0.1345 -0.0630 -0.0437 -0.1249 -0.1561 -0.1790
S-194	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-194	For administration the use of a luer-lock syringe is required .
H-194	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
D-194	-0.4940267503261566	A Luer/ Lock syringe is required for administration .
P-194	-0.7737 -1.1503 -0.3496 -1.7027 -0.5482 -0.9115 -0.1685 -0.0453 -0.0424 -0.1405 -0.6363 -0.2519 -0.3662 -0.1487 -0.1745
S-17	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-17	Total body BMD also increased significantly .
H-17	-0.400558203458786	BMD of the total skeleton was also significantly increased .
D-17	-0.400558203458786	BMD of the total skeleton was also significantly increased .
P-17	-2.1910 -0.1157 -0.2312 -0.1358 -0.1185 -0.5728 -0.5124 -0.1943 -0.8264 -0.0627 -0.2337 -0.1112 -0.1262 -0.1760
S-118	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-118	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-118	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
D-118	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
P-118	-0.1036 -0.3185 -0.2446 -0.1569 -0.1210 -0.8413 -0.9765 -0.0836 -0.1732 -0.1466 -0.0886 -0.0591 -0.1569 -0.2028 -0.1559 -0.1650
S-155	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-155	Method of administration ADVATE should be administered via the intravenous route .
H-155	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
D-155	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
P-155	-3.7308 -0.0119 -0.0096 -0.1823 -0.0309 -0.1600 -0.1934 -0.0669 -0.1389 -0.7407 -0.2678 -0.1681 -0.8657 -0.0771 -0.1345 -0.0630 -0.0437 -0.1249 -0.1561 -0.1790
S-25	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-25	14 Excipients This medicinal product contains lactose and sucrose .
H-25	-0.14292071759700775	Excipients This medicinal product contains lactose and sucrose .
D-25	-0.14292071759700775	Excipients This medicinal product contains lactose and sucrose .
P-25	-0.0114 -0.1603 -0.0946 -0.1048 -0.1305 -0.8114 -0.0796 -0.0732 -0.0985 -0.2431 -0.0370 -0.0859 -0.1411 -0.0483 -0.0706 -0.0717 -0.1333 -0.1771
S-5	Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-5	EU/ 1/ 08/ 447/ 001 EU/ 1/ 08/ 447/ 002 EU/ 1/ 08/ 447/ 003 EU/ 1/ 08/ 447/ 004
H-5	-0.23403407633304596	Blister ( Aclar/ PVC/ aluminium ) Blister ( Aclar/ PVC/ aluminium ) Blister ( Aclar/ PVC/ aluminium )
D-5	-0.23403407633304596	Blister ( Aclar/ PVC/ aluminium ) Blister ( Aclar/ PVC/ aluminium ) Blister ( Aclar/ PVC/ aluminium )
P-5	-0.0026 -0.1564 -0.2122 -0.1828 -0.5236 -0.1493 -0.0829 -0.1755 -0.1448 -0.1237 -0.2860 -0.1037 -0.0630 -0.1761 -0.0154 -0.1426 -0.1209 -0.1596 -0.6252 -0.1199 -0.1961 -0.1434 -0.2854 -0.1323 -0.1267 -0.1600 -0.0459 -0.1455 -0.4283 -0.1517 -0.1603 -0.3865 -0.8261 -0.1180 -0.1990 -0.2538 -0.4365 -0.1343 -0.1364 -0.2644 -0.0518 -0.1443 -1.5707
S-205	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-205	Method of administration ADVATE should be administered via the intravenous route .
H-205	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
D-205	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
P-205	-3.7308 -0.0119 -0.0096 -0.1823 -0.0309 -0.1600 -0.1934 -0.0669 -0.1389 -0.7407 -0.2678 -0.1681 -0.8657 -0.0771 -0.1345 -0.0630 -0.0437 -0.1249 -0.1561 -0.1790
S-180	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-180	Method of administration ADVATE should be administered via the intravenous route .
H-180	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
D-180	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
P-180	-3.7308 -0.0119 -0.0096 -0.1823 -0.0309 -0.1600 -0.1934 -0.0669 -0.1389 -0.7407 -0.2678 -0.1681 -0.8657 -0.0771 -0.1345 -0.0630 -0.0437 -0.1249 -0.1561 -0.1790
S-193	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-193	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-193	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
D-193	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
P-193	-0.1036 -0.3185 -0.2446 -0.1569 -0.1210 -0.8413 -0.9765 -0.0836 -0.1732 -0.1466 -0.0886 -0.0591 -0.1569 -0.2028 -0.1559 -0.1650
S-105	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-105	Method of administration ADVATE should be administered via the intravenous route .
H-105	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
D-105	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
P-105	-3.7308 -0.0119 -0.0096 -0.1823 -0.0309 -0.1600 -0.1934 -0.0669 -0.1389 -0.7407 -0.2678 -0.1681 -0.8657 -0.0771 -0.1345 -0.0630 -0.0437 -0.1249 -0.1561 -0.1790
S-219	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-219	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-219	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
D-219	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
P-219	-0.1036 -0.3185 -0.2446 -0.1569 -0.1210 -0.8413 -0.9765 -0.0836 -0.1732 -0.1466 -0.0886 -0.0591 -0.1569 -0.2028 -0.1559 -0.1650
S-78	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-78	Method of administration ADVATE should be administered via the intravenous route .
H-78	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
D-78	-0.36727389693260193	Method of administration ADVATE is to be administered intravenously .
P-78	-3.7308 -0.0119 -0.0096 -0.1823 -0.0309 -0.1600 -0.1934 -0.0669 -0.1389 -0.7407 -0.2678 -0.1681 -0.8657 -0.0771 -0.1345 -0.0630 -0.0437 -0.1249 -0.1561 -0.1790
S-168	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-168	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-168	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
D-168	-0.249628946185112	For storage conditions of the reconstituted product , see section 6.3 .
P-168	-0.1036 -0.3185 -0.2446 -0.1569 -0.1210 -0.8413 -0.9765 -0.0836 -0.1732 -0.1466 -0.0886 -0.0591 -0.1569 -0.2028 -0.1559 -0.1650
S-12	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-12	4 Excipients This medicinal product contains lactose and sucrose .
H-12	-0.14292071759700775	Excipients This medicinal product contains lactose and sucrose .
D-12	-0.14292071759700775	Excipients This medicinal product contains lactose and sucrose .
P-12	-0.0114 -0.1603 -0.0946 -0.1048 -0.1305 -0.8114 -0.0796 -0.0732 -0.0985 -0.2431 -0.0370 -0.0859 -0.1411 -0.0483 -0.0706 -0.0717 -0.1333 -0.1771
S-30	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-30	Total body BMD also increased significantly .
H-30	-0.400558203458786	BMD of the total skeleton was also significantly increased .
D-30	-0.400558203458786	BMD of the total skeleton was also significantly increased .
P-30	-2.1910 -0.1157 -0.2312 -0.1358 -0.1185 -0.5728 -0.5124 -0.1943 -0.8264 -0.0627 -0.2337 -0.1112 -0.1262 -0.1760
S-292	H-1123 Budapest Tel . : <unk> 361 202 19 80
T-292	H-1123 Budapest Tel . : <<unk>> 361 202 19 80
H-292	-0.1708277016878128	H-1123 Budapest Tel . : <unk> 361 202 19 80
D-292	-0.1708277016878128	H-1123 Budapest Tel . : <unk> 361 202 19 80
P-292	-0.1843 -0.1652 -0.0493 -0.0355 -1.0018 -0.0673 -0.2126 -0.1548 -0.0177 -0.1637 -0.0398 -0.1129 -0.1571 -0.1228 -0.0756 -0.1730
S-99	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-99	Do not remove the blue cap from the BAXJECT II device .
H-99	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
D-99	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
P-99	-0.2281 -0.1107 -0.2299 -0.1420 -0.2793 -0.1726 -0.0992 -0.1450 -0.2088 -2.6118 -0.1257 -0.7366 -0.0732 -0.1118 -0.0974 -0.1364 -0.1810
S-149	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-149	Do not remove the blue cap from the BAXJECT II device .
H-149	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
D-149	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
P-149	-0.2281 -0.1107 -0.2299 -0.1420 -0.2793 -0.1726 -0.0992 -0.1450 -0.2088 -2.6118 -0.1257 -0.7366 -0.0732 -0.1118 -0.0974 -0.1364 -0.1810
S-33	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-33	Further hydroxylation occurs prior to elimination .
H-33	-0.17457881569862366	Further hydroxylation occurs prior to excretion .
D-33	-0.17457881569862366	Further hydroxylation occurs prior to excretion .
P-33	-0.5579 -0.0739 -0.1198 -0.1445 -0.1183 -0.0572 -0.0757 -0.4017 -0.1560 -0.1952 -0.1116 -0.1016 -0.1541 -0.1764
S-20	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-20	Further hydroxylation occurs prior to elimination .
H-20	-0.17457881569862366	Further hydroxylation occurs prior to excretion .
D-20	-0.17457881569862366	Further hydroxylation occurs prior to excretion .
P-20	-0.5579 -0.0739 -0.1198 -0.1445 -0.1183 -0.0572 -0.0757 -0.4017 -0.1560 -0.1952 -0.1116 -0.1016 -0.1541 -0.1764
S-124	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-124	Do not remove the blue cap from the BAXJECT II device .
H-124	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
D-124	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
P-124	-0.2281 -0.1107 -0.2299 -0.1420 -0.2793 -0.1726 -0.0992 -0.1450 -0.2088 -2.6118 -0.1257 -0.7366 -0.0732 -0.1118 -0.0974 -0.1364 -0.1810
S-8	Die empfohlene Dosis beträgt eine Tablette einmal wöchentlich .
T-8	The recommended dose is one tablet once a week .
H-8	-0.19123727083206177	The recommended dose is one tablet once a week .
D-8	-0.19123727083206177	The recommended dose is one tablet once a week .
P-8	-0.3683 -0.1430 -0.0962 -0.1135 -0.1727 -0.1335 -0.0567 -0.2152 -0.5743 -0.1073 -0.1416 -0.1726
S-174	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-174	Do not remove the blue cap from the BAXJECT II device .
H-174	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
D-174	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
P-174	-0.2281 -0.1107 -0.2299 -0.1420 -0.2793 -0.1726 -0.0992 -0.1450 -0.2088 -2.6118 -0.1257 -0.7366 -0.0732 -0.1118 -0.0974 -0.1364 -0.1810
S-199	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-199	Do not remove the blue cap from the BAXJECT II device .
H-199	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
D-199	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
P-199	-0.2281 -0.1107 -0.2299 -0.1420 -0.2793 -0.1726 -0.0992 -0.1450 -0.2088 -2.6118 -0.1257 -0.7366 -0.0732 -0.1118 -0.0974 -0.1364 -0.1810
S-225	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-225	Do not remove the blue cap from the BAXJECT II device .
H-225	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
D-225	-0.3346857726573944	Do not remove the blue protective cap from the BAXJECT II .
P-225	-0.2281 -0.1107 -0.2299 -0.1420 -0.2793 -0.1726 -0.0992 -0.1450 -0.2088 -2.6118 -0.1257 -0.7366 -0.0732 -0.1118 -0.0974 -0.1364 -0.1810
S-286	Normalerweise wird die Ersatztherapie mit ADVATE lebenslang durchgeführt .
T-286	Usually , the replacement therapy with ADVATE is a life-long treatment .
H-286	-0.5511791706085205	Usually , the replacement therapy with ADVATE is lifelong .
D-286	-0.5511791706085205	Usually , the replacement therapy with ADVATE is lifelong .
P-286	-1.1504 -0.0611 -0.2844 -0.2370 -1.4750 -0.1551 -0.1498 -0.1862 -0.1235 -0.1759 -0.0626 -0.1501 -0.0961 -4.0156 -0.3471 -0.5243 -0.1758
S-305	Aerinaze enthält zwei arzneilich wirksame Bestandteile :
T-305	Aerinaze contains two active substances : desloratadine , an antihistamine , and pseudoephedrine , which is a nasal decongestant .
H-305	-0.4388905465602875	Aerinaze contains two medicinal products :
D-305	-0.4388905465602875	Aerinaze contains two medicinal products :
P-305	-0.0779 -0.1412 -0.1384 -0.3955 -0.1005 -0.1542 -0.1201 -2.1637 -0.0649 -1.4142 -0.3018 -0.1943
S-316	Aerinaze ist ebenfalls kontraindiziert bei Patienten mit :
T-316	Aerinaze is also contraindicated in patients with : narrow-angle glaucoma , urinary retention , cardiovascular diseases such as ischaemic heart disease , tachyarrhythmia and severe hypertension , hyperthyroidism ,
H-316	-0.2442682385444641	Aerinaze is also contraindicated in patients with :
D-316	-0.2442682385444641	Aerinaze is also contraindicated in patients with :
P-316	-0.1761 -0.1401 -0.1382 -0.3332 -0.1063 -0.1314 -0.1056 -0.4755 -0.0119 -0.8074 -0.3433 -0.1581 -0.2798 -0.2128
S-312	Blister ( PCTFE<unk> PVC<unk> Alu )
T-312	Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu )
H-312	-0.34397071599960327	Blister ( PCTFE/ PVC/ alu ) Blister ( PCTFE/ PVC/ alu ) Blister ( PCTFE/ PVC/ alu )
D-312	-0.34397071599960327	Blister ( PCTFE/ PVC/ alu ) Blister ( PCTFE/ PVC/ alu ) Blister ( PCTFE/ PVC/ alu )
P-312	-0.0072 -0.2155 -0.1186 -1.7513 -0.1518 -0.1480 -0.1396 -0.1511 -0.1507 -0.1343 -0.1280 -0.3067 -0.2876 -0.3176 -0.1527 -0.0215 -0.1667 -0.1217 -1.8488 -0.1480 -0.1511 -0.1328 -0.1449 -0.1510 -0.2366 -0.1321 -0.1502 -0.3414 -0.2210 -0.1368 -0.2182 -0.1498 -0.1314 -2.3498 -0.1448 -0.1808 -0.1326 -0.1489 -0.1737 -0.2494 -0.1449 -0.1563 -0.5705 -0.3801 -0.1311 -2.2953
S-107	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-107	4.5 Interaction with other medicinal products and other forms of interaction
H-107	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-107	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-107	-0.1536 -0.1445 -0.2979 -0.0228 -0.1428 -0.1516 -0.8008 -0.0394 -0.1084 -0.1863 -0.1457 -0.0114 -0.1547 -0.1634 -0.1564 -0.8373 -0.1612 -0.5813 -0.0233 -0.1996
S-157	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-157	4.5 Interaction with other medicinal products and other forms of interaction
H-157	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-157	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-157	-0.1536 -0.1445 -0.2979 -0.0228 -0.1428 -0.1516 -0.8008 -0.0394 -0.1084 -0.1863 -0.1457 -0.0114 -0.1547 -0.1634 -0.1564 -0.8373 -0.1612 -0.5813 -0.0233 -0.1996
S-80	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-80	4.5 Interaction with other medicinal products and other forms of interaction
H-80	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-80	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-80	-0.1536 -0.1445 -0.2979 -0.0228 -0.1428 -0.1516 -0.8008 -0.0394 -0.1084 -0.1863 -0.1457 -0.0114 -0.1547 -0.1634 -0.1564 -0.8373 -0.1612 -0.5813 -0.0233 -0.1996
S-132	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-132	4.5 Interaction with other medicinal products and other forms of interaction
H-132	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-132	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-132	-0.1536 -0.1445 -0.2979 -0.0228 -0.1428 -0.1516 -0.8008 -0.0394 -0.1084 -0.1863 -0.1457 -0.0114 -0.1547 -0.1634 -0.1564 -0.8373 -0.1612 -0.5813 -0.0233 -0.1996
S-206	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-206	The product contains traces of mouse and hamster proteins .
H-206	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
D-206	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
P-206	-0.7785 -0.1287 -0.4878 -0.1041 -0.1503 -0.3451 -0.1395 -0.2051 -0.0507 -0.0570 -0.3758 -0.0482 -0.1438 -0.2558 -0.1226 -0.1361 -0.1715
S-182	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-182	4.5 Interaction with other medicinal products and other forms of interaction
H-182	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-182	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-182	-0.1536 -0.1445 -0.2979 -0.0228 -0.1428 -0.1516 -0.8008 -0.0394 -0.1084 -0.1863 -0.1457 -0.0114 -0.1547 -0.1634 -0.1564 -0.8373 -0.1612 -0.5813 -0.0233 -0.1996
S-207	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-207	4.5 Interaction with other medicinal products and other forms of interaction
H-207	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-207	-0.22412243485450745	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-207	-0.1536 -0.1445 -0.2979 -0.0228 -0.1428 -0.1516 -0.8008 -0.0394 -0.1084 -0.1863 -0.1457 -0.0114 -0.1547 -0.1634 -0.1564 -0.8373 -0.1612 -0.5813 -0.0233 -0.1996
S-289	Im Kühlschrank lagern ( 2<unk> C-8<unk> C ) .
T-289	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-289	-0.13375510275363922	Store in a refrigerator ( 2<unk> C-8<unk> C ) .
D-289	-0.13375510275363922	Store in a refrigerator ( 2<unk> C-8<unk> C ) .
P-289	-0.3074 -0.1330 -0.1740 -0.1398 -0.0656 -0.1039 -0.1092 -0.1200 -0.1309 -0.0211 -0.1528 -0.2393 -0.1227 -0.0184 -0.1170 -0.1468 -0.1246 -0.1810
S-23	Die Äquivalenz der Einnahme von 5.600 I.E.
T-23	ADROVANCE should not be taken at bedtime or before arising for the day .
H-23	-0.6017589569091797	The equivalent of taking 5,600 IU of supplements
D-23	-0.6017589569091797	The equivalent of taking 5,600 IU of supplements
P-23	-0.5047 -0.0356 -0.1820 -1.3860 -0.1334 -0.0923 -0.1193 -0.0747 -0.4490 -3.9085 -0.0797 -0.2560
S-296	Polska Baxter Poland Sp. z o.o. ul .
T-296	Polska Baxter Poland Sp . z o. o. ul .
H-296	-0.5537326335906982	Polska Baxter Poland Sp. z o.o.
D-296	-0.5537326335906982	Polska Baxter Poland Sp. z o.o.
P-296	-0.2025 -0.0530 -1.0685 -0.1214 -0.1895 -0.4698 -0.1144 -0.1310 -0.0486 -0.2513 -0.4284 -0.0207 -4.0995
S-156	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-156	The product contains traces of mouse and hamster proteins .
H-156	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
D-156	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
P-156	-0.7785 -0.1287 -0.4878 -0.1041 -0.1503 -0.3451 -0.1395 -0.2051 -0.0507 -0.0570 -0.3758 -0.0482 -0.1438 -0.2558 -0.1226 -0.1361 -0.1715
S-181	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-181	The product contains traces of mouse and hamster proteins .
H-181	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
D-181	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
P-181	-0.7785 -0.1287 -0.4878 -0.1041 -0.1503 -0.3451 -0.1395 -0.2051 -0.0507 -0.0570 -0.3758 -0.0482 -0.1438 -0.2558 -0.1226 -0.1361 -0.1715
S-131	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-131	The product contains traces of mouse and hamster proteins .
H-131	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
D-131	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
P-131	-0.7785 -0.1287 -0.4878 -0.1041 -0.1503 -0.3451 -0.1395 -0.2051 -0.0507 -0.0570 -0.3758 -0.0482 -0.1438 -0.2558 -0.1226 -0.1361 -0.1715
S-306	Welchen Nutzen hat Aerinaze in diesen Studien gezeigt ?
T-306	What benefit has Aerinaze shown during the studies ?
H-306	-0.13456571102142334	What benefit has Aerinaze shown during the studies ?
D-306	-0.13456571102142334	What benefit has Aerinaze shown during the studies ?
P-306	-0.0405 -0.0172 -0.1539 -0.1304 -0.1316 -0.1401 -0.2639 -0.1309 -0.0743 -0.1837 -0.1485 -0.1320 -0.1581 -0.1789
S-106	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-106	The product contains traces of mouse and hamster proteins .
H-106	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
D-106	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
P-106	-0.7785 -0.1287 -0.4878 -0.1041 -0.1503 -0.3451 -0.1395 -0.2051 -0.0507 -0.0570 -0.3758 -0.0482 -0.1438 -0.2558 -0.1226 -0.1361 -0.1715
S-79	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-79	The product contains traces of mouse and hamster proteins .
H-79	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
D-79	-0.21767742931842804	There are traces of mouse and hamster proteins in the product .
P-79	-0.7785 -0.1287 -0.4878 -0.1041 -0.1503 -0.3451 -0.1395 -0.2051 -0.0507 -0.0570 -0.3758 -0.0482 -0.1438 -0.2558 -0.1226 -0.1361 -0.1715
S-31	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-31	Protein binding in human plasma is approximately 78 % .
H-31	-0.26593711972236633	Protein binding in human plasma is approximately 78 % .
D-31	-0.26593711972236633	Protein binding in human plasma is approximately 78 % .
P-31	-0.9681 -0.4586 -0.1531 -0.1673 -0.1142 -0.1057 -0.1377 -0.1207 -0.0767 -0.1103 -0.4233 -0.0672 -0.7190 -0.1820 -0.1851
S-18	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-18	Protein binding in human plasma is approximately 78 % .
H-18	-0.26593711972236633	Protein binding in human plasma is approximately 78 % .
D-18	-0.26593711972236633	Protein binding in human plasma is approximately 78 % .
P-18	-0.9681 -0.4586 -0.1531 -0.1673 -0.1142 -0.1057 -0.1377 -0.1207 -0.0767 -0.1103 -0.4233 -0.0672 -0.7190 -0.1820 -0.1851
S-10	Welchen Nutzen hat ADROVANCE in diesen Studien gezeigt ?
T-10	What benefit has ADROVANCE shown during the studies ?
H-10	-0.11430232226848602	What benefit has ADROVANCE shown during the studies ?
D-10	-0.11430232226848602	What benefit has ADROVANCE shown during the studies ?
P-10	-0.0353 -0.0158 -0.1511 -0.0436 -0.0616 -0.1584 -0.0992 -0.1235 -0.0759 -0.2213 -0.1616 -0.1172 -0.1555 -0.1803
S-3	Der Harnsäurespiegel im Blut wurde jeden Monat bestimmt .
T-3	Blood uric acid levels were measured every month .
H-3	-0.5631320476531982	A blood level of uric acid was measured each month .
D-3	-0.5631320476531982	A blood level of uric acid was measured each month .
P-3	-1.2169 -0.1300 -1.8618 -0.1153 -0.1366 -0.1829 -0.5016 -0.3383 -1.2687 -1.1325 -0.0824 -0.1833 -0.1704
S-151	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-151	02 March 2004 Date of last renewal :
H-151	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
D-151	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
P-151	-2.3024 -1.5675 -0.5039 -0.0766 -0.1692 -0.1424 -0.3144 -1.3028 -0.8965 -0.0868 -0.1783 -0.1890
S-101	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-101	02 March 2004 Date of last renewal :
H-101	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
D-101	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
P-101	-2.3024 -1.5675 -0.5039 -0.0766 -0.1692 -0.1424 -0.3144 -1.3028 -0.8965 -0.0868 -0.1783 -0.1890
S-176	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-176	02 March 2004 Date of last renewal :
H-176	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
D-176	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
P-176	-2.3024 -1.5675 -0.5039 -0.0766 -0.1692 -0.1424 -0.3144 -1.3028 -0.8965 -0.0868 -0.1783 -0.1890
S-102	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-102	The dose is determined using the following formula :
H-102	-0.3136082887649536	The necessary dose is calculated using the following formula :
D-102	-0.3136082887649536	The necessary dose is calculated using the following formula :
P-102	-0.5688 -1.4851 -0.0442 -0.4603 -0.0507 -0.1226 -0.2043 -0.1237 -0.1185 -0.2624 -0.1371 -0.1854
S-126	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-126	02 March 2004 Date of last renewal :
H-126	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
D-126	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
P-126	-2.3024 -1.5675 -0.5039 -0.0766 -0.1692 -0.1424 -0.3144 -1.3028 -0.8965 -0.0868 -0.1783 -0.1890
S-227	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-227	02 March 2004 Date of last renewal :
H-227	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
D-227	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
P-227	-2.3024 -1.5675 -0.5039 -0.0766 -0.1692 -0.1424 -0.3144 -1.3028 -0.8965 -0.0868 -0.1783 -0.1890
S-202	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-202	The dose is determined using the following formula :
H-202	-0.3136082887649536	The necessary dose is calculated using the following formula :
D-202	-0.3136082887649536	The necessary dose is calculated using the following formula :
P-202	-0.5688 -1.4851 -0.0442 -0.4603 -0.0507 -0.1226 -0.2043 -0.1237 -0.1185 -0.2624 -0.1371 -0.1854
S-177	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-177	The dose is determined using the following formula :
H-177	-0.3136082887649536	The necessary dose is calculated using the following formula :
D-177	-0.3136082887649536	The necessary dose is calculated using the following formula :
P-177	-0.5688 -1.4851 -0.0442 -0.4603 -0.0507 -0.1226 -0.2043 -0.1237 -0.1185 -0.2624 -0.1371 -0.1854
S-152	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-152	The dose is determined using the following formula :
H-152	-0.3136082887649536	The necessary dose is calculated using the following formula :
D-152	-0.3136082887649536	The necessary dose is calculated using the following formula :
P-152	-0.5688 -1.4851 -0.0442 -0.4603 -0.0507 -0.1226 -0.2043 -0.1237 -0.1185 -0.2624 -0.1371 -0.1854
S-75	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-75	The dose is determined using the following formula :
H-75	-0.3136082887649536	The necessary dose is calculated using the following formula :
D-75	-0.3136082887649536	The necessary dose is calculated using the following formula :
P-75	-0.5688 -1.4851 -0.0442 -0.4603 -0.0507 -0.1226 -0.2043 -0.1237 -0.1185 -0.2624 -0.1371 -0.1854
S-127	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-127	The dose is determined using the following formula :
H-127	-0.3136082887649536	The necessary dose is calculated using the following formula :
D-127	-0.3136082887649536	The necessary dose is calculated using the following formula :
P-127	-0.5688 -1.4851 -0.0442 -0.4603 -0.0507 -0.1226 -0.2043 -0.1237 -0.1185 -0.2624 -0.1371 -0.1854
S-13	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-13	4.5 Interaction with other medicinal products and other forms of interaction
H-13	-0.20850872993469238	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-13	-0.20850872993469238	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-13	-0.1718 -0.1428 -0.1735 -0.0227 -0.1403 -0.1430 -0.6032 -0.0456 -0.1129 -0.1886 -0.1357 -0.0116 -0.1546 -0.1653 -0.1571 -0.7811 -0.1642 -0.6427 -0.0217 -0.1918
S-291	Jede Pulver-Durchstechflasche enthält 250 I.E.
T-291	Each powder vial contains 250 IU octocog alfa .
H-291	-0.24237239360809326	Each powder vial contains 250 IU .
D-291	-0.24237239360809326	Each powder vial contains 250 IU .
P-291	-0.0311 -1.4807 -0.0370 -0.0662 -0.0786 -0.1884 -0.0883 -0.0681 -0.2219 -0.1634
S-26	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-26	4.5 Interaction with other medicinal products and other forms of interaction
H-26	-0.20850872993469238	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-26	-0.20850872993469238	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-26	-0.1718 -0.1428 -0.1735 -0.0227 -0.1403 -0.1430 -0.6032 -0.0456 -0.1129 -0.1886 -0.1357 -0.0116 -0.1546 -0.1653 -0.1571 -0.7811 -0.1642 -0.6427 -0.0217 -0.1918
S-27	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-27	No additional adverse reactions have been identified for ADROVANCE .
H-27	-0.3143737018108368	No other undesirable effects were observed for ADROVANCE .
D-27	-0.3143737018108368	No other undesirable effects were observed for ADROVANCE .
P-27	-0.0369 -0.3371 -0.5163 -0.7570 -0.0532 -0.5145 -0.2461 -0.9817 -0.7263 -0.1340 -0.0718 -0.1622 -0.0977 -0.0870 -0.1288 -0.1793
S-14	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-14	No additional adverse reactions have been identified for ADROVANCE .
H-14	-0.3143737018108368	No other undesirable effects were observed for ADROVANCE .
D-14	-0.3143737018108368	No other undesirable effects were observed for ADROVANCE .
P-14	-0.0369 -0.3371 -0.5163 -0.7570 -0.0532 -0.5145 -0.2461 -0.9817 -0.7263 -0.1340 -0.0718 -0.1622 -0.0977 -0.0870 -0.1288 -0.1793
S-318	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-318	4.5 Interaction with other medicinal products and other forms of interaction
H-318	-0.20850872993469238	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
D-318	-0.20850872993469238	4.5 Interaction with other medicinal products and other forms of forms of forms of interaction
P-318	-0.1718 -0.1428 -0.1735 -0.0227 -0.1403 -0.1430 -0.6032 -0.0456 -0.1129 -0.1886 -0.1357 -0.0116 -0.1546 -0.1653 -0.1571 -0.7811 -0.1642 -0.6427 -0.0217 -0.1918
S-15	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-15	Vitamin D3 is required for normal bone formation .
H-15	-0.4051785171031952	Vitamin D3 is required for normal bone formation .
D-15	-0.4051785171031952	Vitamin D3 is required for normal bone formation .
P-15	-0.1482 -0.0803 -0.1135 -0.2236 -0.1083 -1.5875 -0.1071 -0.2108 -0.0735 -1.8789 -0.1556 -0.1748
S-287	Häufige Nebenwirkungen Schwindel , Kopfschmerzen und Fieber
T-287	Common side effects dizziness , headache and fever .
H-287	-0.1541493833065033	Common side effects Dizziness , headaches and fever
D-287	-0.1541493833065033	Common side effects Dizziness , headaches and fever
P-287	-0.0448 -0.1106 -0.0347 -0.1730 -0.4879 -0.2247 -0.0956 -0.1744 -0.0675 -0.0284 -0.1791 -0.3132 -0.0408 -0.0798 -0.2576
S-28	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-28	Vitamin D3 is required for normal bone formation .
H-28	-0.4051785171031952	Vitamin D3 is required for normal bone formation .
D-28	-0.4051785171031952	Vitamin D3 is required for normal bone formation .
P-28	-0.1482 -0.0803 -0.1135 -0.2236 -0.1083 -1.5875 -0.1071 -0.2108 -0.0735 -1.8789 -0.1556 -0.1748
S-4	Welchen Nutzen hat Adenuric in diesen Studien gezeigt ?
T-4	What benefit has Adenuric shown during the studies ?
H-4	-0.13693851232528687	What benefit has Adenuric shown during the studies ?
D-4	-0.13693851232528687	What benefit has Adenuric shown during the studies ?
P-4	-0.0359 -0.0149 -0.1531 -0.1289 -0.2539 -0.1054 -0.1600 -0.0849 -0.2559 -0.1505 -0.0974 -0.1613 -0.1781
S-282	Was ist ADVATE und wofür wird es angewendet ?
T-282	What ADVATE is and what it is used for 2.
H-282	-0.12713056802749634	What ADVATE is and what it is used for 2.
D-282	-0.12713056802749634	What ADVATE is and what it is used for 2.
P-282	-0.0562 -0.2108 -0.1791 -0.0708 -0.1542 -0.1184 -0.1867 -0.0816 -0.1388 -0.1178 -0.1794 -0.1195 -0.0030 -0.1635
S-201	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-201	02 March 2004 Date of last renewal :
H-201	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
D-201	-0.6441428065299988	02 March 2004 Date of last marketing renewal :
P-201	-2.3024 -1.5675 -0.5039 -0.0766 -0.1692 -0.1424 -0.3144 -1.3028 -0.8965 -0.0868 -0.1783 -0.1890
S-167	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-167	The product may not be returned to refrigerated storage again .
H-167	-0.42477190494537354	Do not store refrigerated .
D-167	-0.42477190494537354	Do not store refrigerated .
P-167	-1.5889 -0.0965 -1.2043 -0.2954 -0.0635 -0.1011 -0.1131 -0.1727 -0.1873
S-117	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-117	The product may not be returned to refrigerated storage again .
H-117	-0.42477190494537354	Do not store refrigerated .
D-117	-0.42477190494537354	Do not store refrigerated .
P-117	-1.5889 -0.0965 -1.2043 -0.2954 -0.0635 -0.1011 -0.1131 -0.1727 -0.1873
S-192	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-192	The product may not be returned to refrigerated storage again .
H-192	-0.42477190494537354	Do not store refrigerated .
D-192	-0.42477190494537354	Do not store refrigerated .
P-192	-1.5889 -0.0965 -1.2043 -0.2954 -0.0635 -0.1011 -0.1131 -0.1727 -0.1873
S-218	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-218	The product may not be returned to refrigerated storage again .
H-218	-0.42477190494537354	Do not store refrigerated .
D-218	-0.42477190494537354	Do not store refrigerated .
P-218	-1.5889 -0.0965 -1.2043 -0.2954 -0.0635 -0.1011 -0.1131 -0.1727 -0.1873
S-142	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-142	The product may not be returned to refrigerated storage again .
H-142	-0.42477190494537354	Do not store refrigerated .
D-142	-0.42477190494537354	Do not store refrigerated .
P-142	-1.5889 -0.0965 -1.2043 -0.2954 -0.0635 -0.1011 -0.1131 -0.1727 -0.1873
S-113	Erkrankungen der Haut und des Unterhautzellgewebes
T-113	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-113	-0.2025551050901413	Skin and subcutaneous tissue disorders
D-113	-0.2025551050901413	Skin and subcutaneous tissue disorders
P-113	-0.1022 -0.1239 -0.1231 -0.9306 -0.2771 -0.0554 -0.1429 -0.0874 -0.0211 -0.1627 -0.0999 -0.3042
S-92	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-92	The product may not be returned to refrigerated storage again .
H-92	-0.42477190494537354	Do not store refrigerated .
D-92	-0.42477190494537354	Do not store refrigerated .
P-92	-1.5889 -0.0965 -1.2043 -0.2954 -0.0635 -0.1011 -0.1131 -0.1727 -0.1873
S-9	Weitere Informationen sind der Packungsbeilage zu entnehmen .
T-9	For more information , see the Package Leaflet .
H-9	-0.11041445285081863	For more information , see the Package Leaflet .
D-9	-0.11041445285081863	For more information , see the Package Leaflet .
P-9	-0.0789 -0.1013 -0.0932 -0.1520 -0.0887 -0.1185 -0.0600 -0.1505 -0.1191 -0.0365 -0.1268 -0.1409 -0.1691
S-315	Die Einnahme kann unabhängig von den Mahlzeiten erfolgen .
T-315	The tablet may be taken with or without food .
H-315	-0.5258001089096069	Taking place regardless of meals .
D-315	-0.5258001089096069	Taking place regardless of meals .
P-315	-0.1322 -2.6592 -0.2286 -0.1605 -0.0936 -0.2149 -0.1916
S-304	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-304	The medicine can only be obtained with a prescription .
H-304	-0.1367090791463852	The medicine can only be obtained with a prescription .
D-304	-0.1367090791463852	The medicine can only be obtained with a prescription .
P-304	-0.1951 -0.1563 -0.1407 -0.1588 -0.1399 -0.0777 -0.0979 -0.1534 -0.0635 -0.1402 -0.1803
S-71	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-71	The medicine can only be obtained with a prescription .
H-71	-0.1367090791463852	The medicine can only be obtained with a prescription .
D-71	-0.1367090791463852	The medicine can only be obtained with a prescription .
P-71	-0.1951 -0.1563 -0.1407 -0.1588 -0.1399 -0.0777 -0.0979 -0.1534 -0.0635 -0.1402 -0.1803
S-7	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-7	The medicine can only be obtained with a prescription .
H-7	-0.1367090791463852	The medicine can only be obtained with a prescription .
D-7	-0.1367090791463852	The medicine can only be obtained with a prescription .
P-7	-0.1951 -0.1563 -0.1407 -0.1588 -0.1399 -0.0777 -0.0979 -0.1534 -0.0635 -0.1402 -0.1803
S-88	Positiver Test auf Antikörper gegen Faktor VIII
T-88	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-88	-0.1837947964668274	Positive test for antibodies to factor VIII
D-88	-0.1837947964668274	Positive test for antibodies to factor VIII
P-88	-0.5578 -0.1053 -0.1097 -0.1433 -0.0209 -0.0839 -0.1674 -0.3816 -0.1937 -0.0667 -0.1914
S-0	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-0	The medicine can only be obtained with a prescription .
H-0	-0.1367090791463852	The medicine can only be obtained with a prescription .
D-0	-0.1367090791463852	The medicine can only be obtained with a prescription .
P-0	-0.1951 -0.1563 -0.1407 -0.1588 -0.1399 -0.0777 -0.0979 -0.1534 -0.0635 -0.1402 -0.1803
S-138	Erkrankungen der Haut und des Unterhautzellgewebes
T-138	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-138	-0.2025551050901413	Skin and subcutaneous tissue disorders
D-138	-0.2025551050901413	Skin and subcutaneous tissue disorders
P-138	-0.1022 -0.1239 -0.1231 -0.9306 -0.2771 -0.0554 -0.1429 -0.0874 -0.0211 -0.1627 -0.0999 -0.3042
S-114	Hämatokritabfall Auffällige Laborwerte
T-114	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-114	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
D-114	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
P-114	-0.4312 -0.0341 -0.2492 -0.1503 -0.0101 -0.1552 -1.5287 -1.1954 -1.2008 -0.1386 -0.0728 -1.2528 -0.2790
S-187	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-187	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-187	-0.8365408778190613	Uncommon Incidences Uncommon
D-187	-0.8365408778190613	Uncommon Incidences Uncommon
P-187	-1.5775 -0.0213 -2.8309 -0.7839 -0.7274 -0.1246 -0.7559 -0.0106 -0.6969
S-215	Hämatokritabfall Auffällige Laborwerte
T-215	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-215	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
D-215	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
P-215	-0.4312 -0.0341 -0.2492 -0.1503 -0.0101 -0.1552 -1.5287 -1.1954 -1.2008 -0.1386 -0.0728 -1.2528 -0.2790
S-189	Hämatokritabfall Auffällige Laborwerte
T-189	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-189	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
D-189	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
P-189	-0.4312 -0.0341 -0.2492 -0.1503 -0.0101 -0.1552 -1.5287 -1.1954 -1.2008 -0.1386 -0.0728 -1.2528 -0.2790
S-164	Hämatokritabfall Auffällige Laborwerte
T-164	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-164	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
D-164	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
P-164	-0.4312 -0.0341 -0.2492 -0.1503 -0.0101 -0.1552 -1.5287 -1.1954 -1.2008 -0.1386 -0.0728 -1.2528 -0.2790
S-139	Hämatokritabfall Auffällige Laborwerte
T-139	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-139	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
D-139	-0.5152369737625122	Haematocrit waste Abnormal laboratory values
P-139	-0.4312 -0.0341 -0.2492 -0.1503 -0.0101 -0.1552 -1.5287 -1.1954 -1.2008 -0.1386 -0.0728 -1.2528 -0.2790
S-163	Erkrankungen der Haut und des Unterhautzellgewebes
T-163	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-163	-0.2025551050901413	Skin and subcutaneous tissue disorders
D-163	-0.2025551050901413	Skin and subcutaneous tissue disorders
P-163	-0.1022 -0.1239 -0.1231 -0.9306 -0.2771 -0.0554 -0.1429 -0.0874 -0.0211 -0.1627 -0.0999 -0.3042
S-213	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-213	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-213	-0.8365408778190613	Uncommon Incidences Uncommon
D-213	-0.8365408778190613	Uncommon Incidences Uncommon
P-213	-1.5775 -0.0213 -2.8309 -0.7839 -0.7274 -0.1246 -0.7559 -0.0106 -0.6969
S-188	Erkrankungen der Haut und des Unterhautzellgewebes
T-188	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-188	-0.2025551050901413	Skin and subcutaneous tissue disorders
D-188	-0.2025551050901413	Skin and subcutaneous tissue disorders
P-188	-0.1022 -0.1239 -0.1231 -0.9306 -0.2771 -0.0554 -0.1429 -0.0874 -0.0211 -0.1627 -0.0999 -0.3042
S-162	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-162	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-162	-0.8365408778190613	Uncommon Incidences Uncommon
D-162	-0.8365408778190613	Uncommon Incidences Uncommon
P-162	-1.5775 -0.0213 -2.8309 -0.7839 -0.7274 -0.1246 -0.7559 -0.0106 -0.6969
S-137	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-137	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-137	-0.8365408778190613	Uncommon Incidences Uncommon
D-137	-0.8365408778190613	Uncommon Incidences Uncommon
P-137	-1.5775 -0.0213 -2.8309 -0.7839 -0.7274 -0.1246 -0.7559 -0.0106 -0.6969
S-112	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-112	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-112	-0.8365408778190613	Uncommon Incidences Uncommon
D-112	-0.8365408778190613	Uncommon Incidences Uncommon
P-112	-1.5775 -0.0213 -2.8309 -0.7839 -0.7274 -0.1246 -0.7559 -0.0106 -0.6969
S-214	Erkrankungen der Haut und des Unterhautzellgewebes
T-214	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-214	-0.2025551050901413	Skin and subcutaneous tissue disorders
D-214	-0.2025551050901413	Skin and subcutaneous tissue disorders
P-214	-0.1022 -0.1239 -0.1231 -0.9306 -0.2771 -0.0554 -0.1429 -0.0874 -0.0211 -0.1627 -0.0999 -0.3042
S-210	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-210	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-210	-0.28185299038887024	Diarrhoea Upper abdominal pain Nausea Vomiting
D-210	-0.28185299038887024	Diarrhoea Upper abdominal pain Nausea Vomiting
P-210	-1.0416 -0.0590 -0.0429 -0.0408 -0.6862 -0.3645 -0.2253 -0.0240 -0.1211 -0.2002 -0.6336 -0.0362 -0.7078 -0.0269 -0.1187 -0.1808
S-184	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-184	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-184	-0.28185299038887024	Diarrhoea Upper abdominal pain Nausea Vomiting
D-184	-0.28185299038887024	Diarrhoea Upper abdominal pain Nausea Vomiting
P-184	-1.0416 -0.0590 -0.0429 -0.0408 -0.6862 -0.3645 -0.2253 -0.0240 -0.1211 -0.2002 -0.6336 -0.0362 -0.7078 -0.0269 -0.1187 -0.1808
S-308	Tablette mit veränderter Wirkstofffreisetzung
T-308	EU/ 1/ 07/ 399/ 001 EU/ 1/ 07/ 399/ 002 EU/ 1/ 07/ 399/ 003 EU/ 1/ 07/ 399/ 004 EU/ 1/ 07/ 399/ 005 EU/ 1/ 07/ 399/ 006
H-308	-0.9518423676490784	Tablet with altered release of active substance
D-308	-0.9518423676490784	Tablet with altered release of active substance
P-308	-3.1014 -0.2893 -0.4886 -0.0634 -2.4733 -0.1582 -1.0154 -0.5323 -0.4447
S-159	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-159	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-159	-0.28185299038887024	Diarrhoea Upper abdominal pain Nausea Vomiting
D-159	-0.28185299038887024	Diarrhoea Upper abdominal pain Nausea Vomiting
P-159	-1.0416 -0.0590 -0.0429 -0.0408 -0.6862 -0.3645 -0.2253 -0.0240 -0.1211 -0.2002 -0.6336 -0.0362 -0.7078 -0.0269 -0.1187 -0.1808
S-253	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-253	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-253	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-253	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-253	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-258	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-258	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-258	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-258	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-258	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-233	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-233	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-233	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-233	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-233	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-236	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-236	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-236	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-236	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-236	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-241	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-241	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-241	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-241	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-241	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-249	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-249	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-249	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-249	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-249	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-278	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-278	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-278	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-278	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-278	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-244	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-244	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-244	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-244	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-244	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-261	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-261	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-261	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-261	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-261	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-266	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-266	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-266	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-266	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-266	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-269	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-269	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-269	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-269	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-269	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-274	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-274	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-274	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-274	-0.06010391563177109	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-274	-0.3247 -0.0586 -0.1928 -0.0475 -0.0462 -0.0656 -0.0713 -0.0085 -0.0255 -0.0212 -0.0297 -0.1481 -0.0358 -0.0157 -0.0686 -0.1541 -0.0180 -0.0337 -0.0031 -0.0112 -0.0176 -0.0638 -0.1307 -0.0258 -0.0231 -0.0281 -0.0180 -0.0432 -0.0162 -0.0034 -0.0123 -0.0418 -0.1799
S-243	79 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-243	73 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-243	-0.21385543048381805	69 PARTICULARS TO APPEAR ON THE BOTTLE OF THE SOLUTION PRODUCT
D-243	-0.21385543048381805	69 PARTICULARS TO APPEAR ON THE BOTTLE OF THE SOLUTION PRODUCT
P-243	-1.3359 -0.0135 -0.0519 -0.0222 -0.1070 -0.0513 -0.0794 -0.0196 -0.0309 -0.0374 -0.0069 -0.0281 -0.0464 -0.0706 -0.1301 -0.1595 -0.0915 -0.0520 -1.5580 -0.0983 -0.1678 -0.6813 -0.1063 -0.0690 -0.1167 -1.0019 -0.2475 -0.0578 -0.0384 -0.0953 -0.1183 -0.1527
S-252	83 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-252	77 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-252	-0.2126646339893341	84 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
D-252	-0.2126646339893341	84 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
P-252	-1.2652 -0.0121 -0.0576 -0.0235 -0.1003 -0.0481 -0.0773 -0.0182 -0.0282 -0.0381 -0.0071 -0.0280 -0.0484 -0.0710 -0.1258 -0.1719 -0.0969 -0.0486 -1.0909 -0.1416 -0.0610 -0.3095 -0.7452 -0.0886 -0.0713 -0.0789 -1.5877 -0.1181 -0.0567 -0.0313 -0.0896 -0.1269 -0.1543
S-235	75 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-235	69 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-235	-0.25377705693244934	75 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
D-235	-0.25377705693244934	75 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
P-235	-2.5789 -0.0143 -0.0555 -0.0215 -0.1029 -0.0455 -0.0742 -0.0194 -0.0283 -0.0369 -0.0068 -0.0272 -0.0484 -0.0696 -0.1280 -0.1617 -0.0926 -0.0500 -1.0438 -0.1219 -0.0614 -0.3014 -0.7761 -0.0969 -0.0749 -0.0864 -1.6781 -0.1200 -0.0552 -0.0310 -0.0879 -0.1279 -0.1501
S-268	91 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-268	85 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-268	-0.25853705406188965	90 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
D-268	-0.25853705406188965	90 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
P-268	-2.6834 -0.0090 -0.0580 -0.0215 -0.1096 -0.0436 -0.0685 -0.0217 -0.0237 -0.0363 -0.0072 -0.0273 -0.0532 -0.0728 -0.1392 -0.1563 -0.0977 -0.0508 -1.0738 -0.1287 -0.0630 -0.3082 -0.8054 -0.0968 -0.0683 -0.0807 -1.6539 -0.1187 -0.0566 -0.0323 -0.0897 -0.1246 -0.1511
S-277	95 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-277	89 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-277	-0.2217426300048828	95 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
D-277	-0.2217426300048828	95 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
P-277	-1.5041 -0.0092 -0.0601 -0.0207 -0.0932 -0.0454 -0.0725 -0.0253 -0.0241 -0.0370 -0.0073 -0.0256 -0.0579 -0.0703 -0.1349 -0.1576 -0.0969 -0.0485 -1.0563 -0.1344 -0.0619 -0.3318 -0.7716 -0.0955 -0.0720 -0.0801 -1.6470 -0.1187 -0.0556 -0.0317 -0.0883 -0.1267 -0.1553
S-260	87 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-260	81 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-260	-0.24788948893547058	87 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
D-260	-0.24788948893547058	87 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION PRODUCT
P-260	-2.3972 -0.0115 -0.0551 -0.0215 -0.0993 -0.0508 -0.0708 -0.0235 -0.0211 -0.0359 -0.0070 -0.0273 -0.0494 -0.0678 -0.1279 -0.1700 -0.0954 -0.0521 -1.0807 -0.1323 -0.0615 -0.3288 -0.7578 -0.0935 -0.0671 -0.0809 -1.6195 -0.1178 -0.0564 -0.0311 -0.0864 -0.1262 -0.1567
S-297	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
T-297	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <<unk>> 354 533 6100
H-297	-0.3165941834449768	Suðurland Bride 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
D-297	-0.3165941834449768	Suðurland Bride 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
P-297	-0.0723 -2.5927 -0.1016 -1.9791 -1.2706 -0.1826 -0.0470 -0.1522 -0.1449 -0.0537 -0.1156 -0.1265 -0.0842 -0.9152 -0.0873 -0.0340 -0.0684 -0.0907 -0.0293 -0.0347 -0.1538 -0.0373 -0.1650 -0.0661 -0.0966 -0.0926 -0.1354 -0.0822 -0.1694
S-283	WAS IST ADVATE UND WOFÜR WIRD ES ANGEWENDET ?
T-283	WHAT ADVATE IS AND WHAT IT IS USED FOR
H-283	-0.10619868338108063	WHAT ADVATE IS AND WHAT IT IS USED FOR
D-283	-0.10619868338108063	WHAT ADVATE IS AND WHAT IT IS USED FOR
P-283	-0.0626 -0.0200 -0.1713 -0.2126 -0.0526 -0.2830 -0.0256 -0.0291 -0.0113 -0.0211 -0.0358 -0.0375 -0.0132 -0.0239 -0.6102 -0.0660 -0.1296
S-279	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-279	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-279	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-279	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-279	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-240	78 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-240	72 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-240	-0.11834728717803955	78 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-240	-0.11834728717803955	78 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-240	-1.3511 -0.1260 -0.0662 -0.1244 -0.0813 -0.1106 -0.0638 -0.0558 -0.0215 -0.0611 -0.0427 -0.0673 -0.0107 -0.0382 -0.0445 -0.0061 -0.0290 -0.0696 -0.0425 -0.0318 -0.0127 -0.2924 -0.0095 -0.0316 -0.1979 -0.0366 -0.1576 -0.0506 -0.1807 -0.0938 -0.0030 -0.2755 -0.0415 -0.1964
S-276	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-276	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-276	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-276	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-276	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-232	74 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-232	68 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-232	-0.10717158019542694	74 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-232	-0.10717158019542694	74 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-232	-0.9820 -0.1280 -0.0738 -0.1264 -0.0775 -0.1072 -0.0676 -0.0557 -0.0217 -0.0618 -0.0444 -0.0669 -0.0105 -0.0386 -0.0430 -0.0057 -0.0287 -0.0642 -0.0425 -0.0334 -0.0117 -0.2885 -0.0092 -0.0316 -0.1998 -0.0327 -0.1567 -0.0474 -0.1909 -0.0929 -0.0028 -0.2615 -0.0387 -0.1998
S-267	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-267	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-267	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-267	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-267	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-248	82 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-248	76 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-248	-0.11438744515180588	82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-248	-0.11438744515180588	82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-248	-1.2493 -0.1248 -0.0662 -0.1240 -0.0784 -0.1113 -0.0682 -0.0561 -0.0213 -0.0587 -0.0407 -0.0661 -0.0126 -0.0356 -0.0429 -0.0059 -0.0276 -0.0668 -0.0435 -0.0317 -0.0122 -0.2657 -0.0089 -0.0319 -0.1957 -0.0345 -0.1528 -0.0508 -0.1844 -0.0916 -0.0027 -0.2952 -0.0397 -0.1916
S-257	86 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-257	80 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-257	-0.1218792125582695	86 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-257	-0.1218792125582695	86 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-257	-1.5041 -0.1233 -0.0674 -0.1233 -0.0802 -0.1077 -0.0579 -0.0532 -0.0212 -0.0581 -0.0411 -0.0662 -0.0134 -0.0334 -0.0433 -0.0060 -0.0258 -0.0684 -0.0418 -0.0328 -0.0125 -0.2581 -0.0088 -0.0323 -0.1942 -0.0362 -0.1476 -0.0536 -0.1868 -0.0927 -0.0028 -0.3115 -0.0398 -0.1986
S-265	90 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-265	84 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-265	-0.09302472323179245	90 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-265	-0.09302472323179245	90 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-265	-0.5254 -0.1363 -0.0725 -0.1317 -0.0788 -0.1071 -0.0545 -0.0499 -0.0220 -0.0589 -0.0424 -0.0666 -0.0130 -0.0272 -0.0429 -0.0057 -0.0276 -0.0694 -0.0411 -0.0331 -0.0125 -0.2805 -0.0089 -0.0313 -0.1993 -0.0354 -0.1472 -0.0508 -0.1798 -0.0904 -0.0025 -0.2740 -0.0393 -0.2049
S-273	94 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-273	88 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-273	-0.11881431192159653	94 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-273	-0.11881431192159653	94 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-273	-1.3393 -0.1304 -0.0723 -0.1319 -0.0765 -0.1067 -0.0522 -0.0550 -0.0213 -0.0599 -0.0425 -0.0690 -0.0139 -0.0315 -0.0421 -0.0056 -0.0272 -0.0690 -0.0431 -0.0316 -0.0126 -0.3101 -0.0097 -0.0324 -0.2009 -0.0357 -0.1420 -0.0514 -0.1954 -0.0921 -0.0032 -0.2892 -0.0420 -0.2018
S-19	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-19	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden . Circulating vitamin D3 is bound to vitamin D-binding protein .
H-19	-0.3128005266189575	Circulating vitamin D3 is bound to vitamin D-binding protein .
D-19	-0.3128005266189575	Circulating vitamin D3 is bound to vitamin D-binding protein .
P-19	-2.4357 -0.0215 -0.1935 -0.0615 -0.0819 -0.1044 -0.2324 -0.1095 -0.1856 -0.4345 -0.6570 -0.0523 -0.3911 -0.0964 -0.3250 -0.1307 -0.0672 -0.1839 -0.1793
S-270	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-270	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-270	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-270	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-270	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-259	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-259	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-259	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-259	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-259	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-262	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-262	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-262	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-262	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-262	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-203	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-203	Factor VIII level required ( % or IU/ dl )
H-203	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
D-203	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
P-203	-1.2413 -0.2562 -0.6610 -0.1574 -0.3934 -0.9426 -0.6122 -0.3118 -0.0554 -0.0443 -0.0546 -0.0078 -0.0972 -0.1488 -0.1198 -0.1395 -0.1512 -0.0848 -0.1735 -0.0491 -0.1452 -0.2036
S-32	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-32	Circulating vitamin D3 is bound to vitamin D-binding protein .
H-32	-0.3128005266189575	Circulating vitamin D3 is bound to vitamin D-binding protein .
D-32	-0.3128005266189575	Circulating vitamin D3 is bound to vitamin D-binding protein .
P-32	-2.4357 -0.0215 -0.1935 -0.0615 -0.0819 -0.1044 -0.2324 -0.1095 -0.1856 -0.4345 -0.6570 -0.0523 -0.3911 -0.0964 -0.3250 -0.1307 -0.0672 -0.1839 -0.1793
S-76	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-76	Factor VIII level required ( % or IU/ dl )
H-76	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
D-76	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
P-76	-1.2413 -0.2562 -0.6610 -0.1574 -0.3934 -0.9426 -0.6122 -0.3118 -0.0554 -0.0443 -0.0546 -0.0078 -0.0972 -0.1488 -0.1198 -0.1395 -0.1512 -0.0848 -0.1735 -0.0491 -0.1452 -0.2036
S-103	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-103	Factor VIII level required ( % or IU/ dl )
H-103	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
D-103	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
P-103	-1.2413 -0.2562 -0.6610 -0.1574 -0.3934 -0.9426 -0.6122 -0.3118 -0.0554 -0.0443 -0.0546 -0.0078 -0.0972 -0.1488 -0.1198 -0.1395 -0.1512 -0.0848 -0.1735 -0.0491 -0.1452 -0.2036
S-128	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-128	Factor VIII level required ( % or IU/ dl )
H-128	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
D-128	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
P-128	-1.2413 -0.2562 -0.6610 -0.1574 -0.3934 -0.9426 -0.6122 -0.3118 -0.0554 -0.0443 -0.0546 -0.0078 -0.0972 -0.1488 -0.1198 -0.1395 -0.1512 -0.0848 -0.1735 -0.0491 -0.1452 -0.2036
S-153	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-153	Factor VIII level required ( % or IU/ dl )
H-153	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
D-153	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
P-153	-1.2413 -0.2562 -0.6610 -0.1574 -0.3934 -0.9426 -0.6122 -0.3118 -0.0554 -0.0443 -0.0546 -0.0078 -0.0972 -0.1488 -0.1198 -0.1395 -0.1512 -0.0848 -0.1735 -0.0491 -0.1452 -0.2036
S-254	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-254	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-254	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-254	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-254	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-178	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-178	Factor VIII level required ( % or IU/ dl )
H-178	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
D-178	-0.2750197649002075	Necessary factor VIII plasma concentrations ( % or IU/ dl )
P-178	-1.2413 -0.2562 -0.6610 -0.1574 -0.3934 -0.9426 -0.6122 -0.3118 -0.0554 -0.0443 -0.0546 -0.0078 -0.0972 -0.1488 -0.1198 -0.1395 -0.1512 -0.0848 -0.1735 -0.0491 -0.1452 -0.2036
S-234	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-234	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-234	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-234	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-234	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-237	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-237	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-237	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-237	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-237	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-242	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-242	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-242	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-242	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-242	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-245	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-245	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-245	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-245	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-245	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-251	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-251	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-251	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-251	-0.0991150438785553	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-251	-0.1862 -0.0903 -0.2754 -0.0479 -0.0239 -0.0083 -0.0393 -0.1192 -0.1332 -0.1249 -0.1666 -0.0445 -0.0238 -0.1489 -0.1277 -0.0469 -0.0161 -0.0443 -0.2527 -0.0373 -0.0439 -0.1164 -0.0833 -0.1778
S-6	Filmtablette Zum Einnehmen Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-6	Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu )
H-6	-0.24270574748516083	Film-coated oral tablet Blister ( Aclar/ PVC/ aluminium ) Blister ( Aclar/ PVC/ aluminium )
D-6	-0.24270574748516083	Film-coated oral tablet Blister ( Aclar/ PVC/ aluminium ) Blister ( Aclar/ PVC/ aluminium )
P-6	-1.8244 -0.0373 -0.2654 -0.1116 -0.1107 -0.0337 -0.0840 -0.0151 -0.1289 -0.1241 -0.1506 -0.3691 -0.1103 -0.1514 -0.1632 -0.1476 -0.1354 -0.5627 -0.1068 -0.0383 -0.1493 -1.2669 -0.1476 -0.1894 -0.1179 -0.4255 -0.0988 -0.1978 -0.1433 -0.4045 -0.1296 -0.1159 -0.1735 -0.0346 -0.1461 -0.3263
S-34	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-34	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-34	-0.35733935236930847	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-34	-0.35733935236930847	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-34	-0.5577 -0.1596 -1.3439 -0.0475 -0.1564 -0.3482 -0.1536 -0.5019 -0.1865 -0.3826 -0.1523 -2.2228 -0.0928 -0.1100 -0.1531 -0.1431 -0.0497 -0.0679 -0.1490 -0.1682
S-21	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-21	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-21	-0.35733935236930847	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-21	-0.35733935236930847	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-21	-0.5577 -0.1596 -1.3439 -0.0475 -0.1564 -0.3482 -0.1536 -0.5019 -0.1865 -0.3826 -0.1523 -2.2228 -0.0928 -0.1100 -0.1531 -0.1431 -0.0497 -0.0679 -0.1490 -0.1682
S-11	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-11	ADROVANCE reduces the risk of vertebral and hip fractures .
H-11	-0.23844143748283386	ADROVANCE decreases the risk of vertebral and hip fractures .
D-11	-0.23844143748283386	ADROVANCE decreases the risk of vertebral and hip fractures .
P-11	-0.0637 -0.0597 -0.1678 -0.0960 -0.1112 -1.8535 -0.1646 -0.1248 -0.0738 -0.1587 -1.0175 -0.0902 -0.0218 -0.1007 -0.1478 -0.0684 -0.0416 -0.0871 -0.1397 -0.1801
S-319	Desloratadin und Pseudoephedrin gehen in die Muttermilch über .
T-319	Desloratadine and pseudoephedrine are both excreted in breast milk .
H-319	-0.47110021114349365	Desloratadine and pseudoephedrine are excreted in human milk .
D-319	-0.47110021114349365	Desloratadine and pseudoephedrine are excreted in human milk .
P-319	-2.0080 -0.0409 -0.1713 -0.3818 -0.3488 -0.1550 -0.2338 -3.1094 -0.2198 -0.0760 -0.1555 -0.1762 -0.0871 -0.3231 -1.4691 -0.2717 -0.0799 -0.3041 -0.0889 -0.3436 -0.1474 -0.1727
S-22	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-22	ADROVANCE reduces the risk of vertebral and hip fractures .
H-22	-0.23844143748283386	ADROVANCE decreases the risk of vertebral and hip fractures .
D-22	-0.23844143748283386	ADROVANCE decreases the risk of vertebral and hip fractures .
P-22	-0.0637 -0.0597 -0.1678 -0.0960 -0.1112 -1.8535 -0.1646 -0.1248 -0.0738 -0.1587 -1.0175 -0.0902 -0.0218 -0.1007 -0.1478 -0.0684 -0.0416 -0.0871 -0.1397 -0.1801
S-229	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
T-229	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-229	-0.49420323967933655	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
D-229	-0.49420323967933655	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
P-229	-0.9738 -0.1192 -0.2082 -0.3542 -1.1706 -0.0815 -2.9552 -1.0299 -0.1703 -0.1708 -0.0537 -0.1716 -0.1430 -0.3542 -0.1108 -0.1859 -0.0837 -0.2122 -1.1592 -0.1759
S-299	Internationaler Freiname ( INN ) : Contusugene Ladenovec
T-299	International non-proprietary name ( INN ) : contusugene ladenovec
H-299	-0.6733521819114685	International Freiname ( INN ) : Contusugene Ladenovec
D-299	-0.6733521819114685	International Freiname ( INN ) : Contusugene Ladenovec
P-299	-0.1777 -2.9998 -0.1584 -0.2777 -0.1803 -0.1509 -0.1184 -0.1455 -0.1854 -1.6711 -0.3903 -0.1123 -0.1451 -3.6635 -0.1921 -0.1560 -0.1388 -1.2568
S-294	4 D-85716 Unterschleißheim Tel : <unk> 49 89 31 701
T-294	4 D-85716 Unterschleißheim Tel : <<unk>> 49 89 31 701
H-294	-0.4093664288520813	4 D-85716 Unterschleisheim Tel : <unk> 49 89 31 701
D-294	-0.4093664288520813	4 D-85716 Unterschleisheim Tel : <unk> 49 89 31 701
P-294	-0.7720 -0.1003 -0.2059 -0.1081 -1.3509 -0.1265 -0.0851 -2.3373 -0.1114 -1.5969 -0.0433 -0.1586 -0.0176 -0.0584 -0.1848 -0.0740 -0.1758 -0.0973 -0.1737
S-298	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-298	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-298	-0.22942252457141876	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
D-298	-0.22942252457141876	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
P-298	-0.0968 -0.3021 -1.5980 -0.1544 -0.0673 -0.2274 -0.1042 -0.1563 -0.1993 -0.0102 -0.2667 -0.1521 -0.1464 -0.2066 -0.1356 -0.0508 -0.1617 -0.1544 -0.1689
S-295	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-295	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-295	-0.22942252457141876	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
D-295	-0.22942252457141876	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
P-295	-0.0968 -0.3021 -1.5980 -0.1544 -0.0673 -0.2274 -0.1042 -0.1563 -0.1993 -0.0102 -0.2667 -0.1521 -0.1464 -0.2066 -0.1356 -0.0508 -0.1617 -0.1544 -0.1689
S-255	300 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-255	300 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-255	-0.27835050225257874	300 IU/ ml by reconstitution Specific activity : approximately
D-255	-0.27835050225257874	300 IU/ ml by reconstitution Specific activity : approximately
P-255	-0.0638 -0.1323 -0.0544 -0.1686 -0.0682 -0.5756 -0.1019 -0.0520 -0.1867 -0.0976 -0.0925 -0.1523 -1.0926 -1.0583
S-246	200 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-246	200 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-246	-0.3829617500305176	200 IU/ ml by reconstitution Specific activity : approximately
D-246	-0.3829617500305176	200 IU/ ml by reconstitution Specific activity : approximately
P-246	-1.8401 -0.1248 -0.0520 -0.1673 -0.0695 -0.5095 -0.1131 -0.0491 -0.1799 -0.0973 -0.0882 -0.1525 -1.0879 -0.8303
S-238	100 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-238	100 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-238	-0.3345690667629242	100 IU/ ml by reconstitution Specific activity : approximately
D-238	-0.3345690667629242	100 IU/ ml by reconstitution Specific activity : approximately
P-238	-0.9580 -0.1334 -0.0542 -0.1661 -0.0678 -0.6383 -0.1061 -0.0516 -0.1646 -0.0964 -0.0973 -0.1525 -1.0794 -0.9182
S-263	400 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-263	400 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-263	-0.33526161313056946	400 IU/ ml by reconstitution Specific activity : approximately
D-263	-0.33526161313056946	400 IU/ ml by reconstitution Specific activity : approximately
P-263	-1.0855 -0.1311 -0.0546 -0.1697 -0.0685 -0.5392 -0.1083 -0.0503 -0.1768 -0.0952 -0.0934 -0.1520 -1.0212 -0.9477
S-271	600 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-271	600 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-271	-0.28269386291503906	600 IU/ ml by reconstitution Specific activity : approximately
D-271	-0.28269386291503906	600 IU/ ml by reconstitution Specific activity : approximately
P-271	-0.1760 -0.1360 -0.0557 -0.1674 -0.0663 -0.5181 -0.1034 -0.0536 -0.1762 -0.1033 -0.0949 -0.1506 -1.1007 -1.0553
S-1	Durch die Verminderung der Harnsäureproduktion kann Adenuric die
T-1	By reducing the production of uric acid , Adenuric can reduce levels of uric acid in the blood and keep them low , stopping crystals from building up .
H-1	-0.6893796920776367	By reducing the production of uric acid , adenuric has the potential to reduce the
D-1	-0.6893796920776367	By reducing the production of uric acid , adenuric has the potential to reduce the
P-1	-1.7801 -0.8429 -1.1058 -0.2265 -0.1465 -0.5121 -0.1611 -0.2100 -0.2484 -0.6618 -0.0595 -0.1858 -3.9795 -0.2955 -0.1823 -0.1644 -1.3634 -0.1204 -0.8524
S-230	50 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-230	50 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-230	-0.26648369431495667	50 IU/ ml by reconstitution Specific activity : approximately
D-230	-0.26648369431495667	50 IU/ ml by reconstitution Specific activity : approximately
P-230	-0.1183 -0.1286 -0.0563 -0.1657 -0.0670 -0.6298 -0.1037 -0.0495 -0.1735 -0.0926 -0.0908 -0.1520 -1.1097 -0.7932
2021-01-23 10:26:33 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-23 10:26:33 | INFO | fairseq_cli.generate | Translated 320 sentences (5476 tokens) in 3.5s (90.85 sentences/s, 1554.69 tokens/s)
2021-01-23 10:26:33 | WARNING | root | That's 100 lines that end in a tokenized period ('.')
2021-01-23 10:26:33 | WARNING | root | It looks like you forgot to detokenize your test data, which may hurt your score.
2021-01-23 10:26:33 | WARNING | root | If you insist your data is detokenized, or don't care, you can suppress this message with '--force'.
Generate test with beam=5: BLEU = 33.42 62.3/49.8/41.9/34.5 (BP = 0.726 ratio = 0.758 hyp_len = 3279 ref_len = 4328)


###############################################################################
Peregrine Cluster
Job 17599371 for user 's3475743'
Finished at: Sat Jan 23 10:26:34 CET 2021

Job details:
============

Job ID              : 17599371
Name                : g_EMEA11_short
User                : s3475743
Partition           : gpu
Nodes               : pg-gpu31
Number of Nodes     : 1
Cores               : 12
State               : COMPLETED
Submit              : 2021-01-23T09:38:50
Start               : 2021-01-23T10:26:10
End                 : 2021-01-23T10:26:34
Reserved walltime   : 23:55:00
Used walltime       : 00:00:24
Used CPU time       : 00:00:17 (efficiency:  6.05%)
% User (Computation): 75.69%
% System (I/O)      : 24.30%
Mem reserved        : 32G/node
Max Mem used        : 0.00  (pg-gpu31)
Max Disk Write      : 0.00  (pg-gpu31)
Max Disk Read       : 0.00  (pg-gpu31)
Average GPU usage   : 38.0% (pg-gpu31)


Acknowledgements:
=================

Please see this page for information about acknowledging Peregrine in your publications:

https://wiki.hpc.rug.nl/peregrine/introduction/scientific_output

################################################################################
